

Independent Auditor's Report

To the Members of International Hospital Limited

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of International Hospital Limited (the "Company") which comprise the balance sheet as at 31 March 2026, and the statement of profit and loss (including other comprehensive income), statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2026, and its profit and other comprehensive loss, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial statements.

Emphasis of Matter

- a. We draw attention to Note 24 of the financial statements which describes the accounting for the Composite Scheme of Arrangement between Fortis Hospitals Limited ('FHSL') ('transferor company') and the Company and Fortis Hospotel Limited ('FHTL') (together referred to as 'transferee companies'). The Scheme has been approved by the Hon'ble National Company Law Tribunal, Delhi Bench ('NCLT') vide its order dated 09 May 2025 and the Hon'ble National Company Law Tribunal ('NCLT'), Chandigarh Bench, vide its order dated 30 July 2025 with an appointed date of 01 April 2023 and a certified copy has been filed by the Company with the Registrar of Companies, Haryana, on 01 September 2025. Accordingly, the amounts relating to the year ended 31 March 2026 include the impact of the business combination for the entire year and the corresponding amounts for the previous year ended 31 March 2025 have been restated by the Company after recognising the effect of the Scheme as if it had occurred from the beginning of the preceding period. The aforesaid note also describes in detail the impact of the business combination on the financial statements.

Our opinion is not modified in respect of this matter.

Other Information

The Company's Management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's directors' report, but does not include the financial statements and auditor's report thereon.

Independent Auditor's Report (Continued)

International Hospital Limited

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's and Board of Directors' Responsibilities for the Financial Statements

The Company's Management and Board of Directors are responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the state of affairs, profit/ loss and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting in preparation of financial statements and, based on the audit evidence obtained, whether a

Independent Auditor's Report (Continued)**International Hospital Limited**

material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
- 2 A. As required by Section 143(3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books except for the matter stated in the paragraph 2B(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.
 - c. The balance sheet, the statement of profit and loss (including other comprehensive income), the statement of changes in equity and the statement of cash flows dealt with by this Report are in agreement with the books of account.
 - d. In our opinion, the aforesaid financial statements comply with the Ind AS specified under Section 133 of the Act.
 - e. On the basis of the written representations received from the directors as on 1 April 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2026 from being appointed as a director in terms of Section 164(2) of the Act.
 - f. the modification relating to the maintenance of accounts and other matters connected therewith are as stated in the paragraph 2A(b) above on reporting under Section 143(3)(b) of the Act and paragraph 2B(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.
 - g. With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
- B. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - a. The Company has disclosed the impact of pending litigations as at 31 March 2026 on its financial position in its financial statements - Refer Note 16 to the financial statements.

Independent Auditor's Report (Continued)

International Hospital Limited

- b. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- c. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
- d (i) The management has represented that, to the best of its knowledge and belief, as disclosed in the Note 21(iii) to the financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- (ii) The management has represented that, to the best of its knowledge and belief, as disclosed in the Note 21(iv) to the financial statements, no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Parties ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- (iii) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (i) and (ii) above, contain any material misstatement.
- e. The Company has neither declared nor paid any dividend during the year.
- f. Based on our examination which included test checks, except for the instance mentioned below, the Company has used accounting software for maintaining its books of account, which have a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the respective software:
 - i. The feature of recording audit trail (edit log) facility was not enabled on certain non-editable fields/ tables of the accounting software used for maintaining the books of account relating to revenue and consumption records.Further, where audit trail (edit log) facility was enabled and operated for the respective accounting software, we did not come across any instance of the audit trail feature being tampered with.
Additionally, except to the extent audit trail was not enabled, the audit trail has been preserved by the Company as per the statutory requirements for record retention.

Independent Auditor's Report (Continued)

International Hospital Limited

C. With respect to the matter to be included in the Auditor's Report under Section 197(16) of the Act:

In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) of the Act which are required to be commented upon by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Rakesh Dewan

Partner

Place: Gurugram

Date: 18 May 2026

Membership No.: 092212

ICAI UDIN:26092212ZNHUFY9505

Annexure A to the Independent Auditor’s Report on the Financial Statements of International Hospital Limited for the year ended 31 March 2026

(Referred to in paragraph 1 under ‘Report on Other Legal and Regulatory Requirements’ section of our report of even date)

- (i) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.
- (B) The Company has maintained proper records showing full particulars of intangible assets.
- (i) (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has a regular programme of physical verification of its Property, Plant and Equipment by which all property, plant and equipment are verified at least once over a period of two years. In accordance with this programme, certain property, plant and equipment were verified during the year. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the leases agreements are duly executed in favour of the lessee) disclosed in the financial statements are held in the name of the Company, except for the following which are not held in the name of the Company:

Description of property	Gross carrying value(Rupees in lacs)	Held in the name of	Whether promoter, director or their relative or employee	Period held- indicate range, where appropriate	Reason for not being held in the name of the Company. Also indicate if in dispute
Land in Faridabad	6,151.08	Escorts Hospital and Research Centre Limited	No	Since 2014	The title deeds are in the name of Escorts Hospital and Research Centre Limited, erstwhile Company that was merged with the Company subsequent to a scheme of merger sanctioned by the High Court of Punjab and Haryana, which came into effect on January 17, 2014.
Land in Mulund,	30,190.00	Kanishka Healthcare	No	Since 2014	The title deeds are in the name

Annexure A to the Independent Auditor's Report on the Financial Statements of International Hospital Limited for the year ended 31 March 2026 (Continued)

Description of property	Gross carrying value(Rupees in lacs)	Held in the name of	Whether promoter, director or their relative or employee	Period held-indicate range, where appropriate	Reason for not being held in the name of the Company. Also indicate if in dispute
Mumbai		Limited			of Kanishka Healthcare Limited, erstwhile Company that was merged with the Company subsequent to a scheme of merger sanctioned by the High Court of Punjab and Haryana, which came into effect on January 17, 2014.
Land in Kolkata	1,230.17	Fortis Hospitals Limited	No	Since 2023	The title deeds are in the name of Fortis Hospitals Limited (FHsL). Pursuant to the composite scheme of arrangement sanctioned by the NCLT of Chandigarh and Delhi Bench, some undertakings of FHsL were merged with the Company, with an appointed date of April 01, 2023.

In case of immovable property situated at Anandpur- Kolkata location, the title deed is under dispute. The Company has been legally advised that it has the title deed in its name for the aforesaid immovable property and that it will be able to defend any counter claims against it.

Annexure A to the Independent Auditor’s Report on the Financial Statements of International Hospital Limited for the year ended 31 March 2026 (Continued)

- (d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year.
- (e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.
- (ii) (a) The inventory, has been physically verified by the management during the year. In our opinion, the frequency of such verification is reasonable and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and the book records that were more than 10% in the aggregate of each class of inventory
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets. In our opinion, the quarterly returns or statements filed by the Company with such banks or financial institutions are in agreement with the books of account of the Company.
- (iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured to companies, firms, limited liability partnerships or any other parties during the year. Accordingly, provisions of clauses 3(iii)(a) of the Order are not applicable to the Company. The Company has made investments in companies during the year and has granted advances in the nature of loans to other parties in the earlier years, in respect of which the requisite information is as below. The Company has not made any investments in firms, limited liability partnerships or any other parties during the year.
- (b) According to the information and explanations given to us and based on the audit procedures conducted by us, in our opinion, the terms and conditions of the investments made during the year are, prima facie, not prejudicial to the interest of the Company.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, in case of advances in the nature of loans given as listed below, schedule of repayment of principal and payment of interest has not been stipulated and accordingly we are unable to comment on whether the repayments or receipts are regular:

Name of the entity	Amount (Rupees in lacs)	Nature	Remarks
Fortis Education Society	294.66	Advances in the nature of loans	These amounts have been fully provided for in books.

- (d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, in case of advances in the nature of loans given in clause (c) above, the schedule for repayment of principal and payment of interest have not been stipulated and accordingly we are unable to comment on the amount overdue for more than ninety days
- (e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loan or advance in the nature of loan granted falling due during the year, which has been renewed or extended or fresh loans granted to settle the overdues of existing loans given to same parties.
- (f) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not granted any loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment.

Annexure A to the Independent Auditor’s Report on the Financial Statements of International Hospital Limited for the year ended 31 March 2026 (Continued)

- (iv) According to the information and explanations given to us and on the basis of our examination of records of the Company, in respect of investments made and loans, guarantees and security given by the Company, in our opinion the provisions of Section 185 and 186 of the Companies Act, 2013 (“the Act”) have been complied with.
- (v) The Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.
- (vi) We have broadly reviewed the books of accounts maintained by the Company pursuant to the rules prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Act in respect of its sales of goods and services provided by it and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. However, we have not carried out a detailed examination of the records with a view to determine whether these are accurate or complete.
- (vii) (a) The Company does not have liability in respect of Service tax, Duty of excise, Sales tax and Value added tax during the year since effective 1 July 2017, these statutory dues has been subsumed into GST.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, in our opinion, the undisputed statutory dues including Goods and Service Tax, Provident fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues have generally been regularly deposited with the appropriate authorities, though there have been slight delays in a few cases of Provident fund (PF), Goods and Service Tax (GST) and National Pension Scheme (NPS).

According to the information and explanations given to us and on the basis of our examination of the records of the Company, no undisputed amounts payable in respect of Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues were in arrears as at 31 March 2026 for a period of more than six months from the date they became payable.

- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, statutory dues relating to Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues which have not been deposited on account of any dispute are as follows:

Name of the statute	Nature of the dues	Amount (Rs. in lacs)	Amount Paid under protest (Rs. in lacs)	Period to which the amount relates	Forum where dispute is pending
Income Tax Act, 1961	Income Tax and interest thereon	4,220.01	606.82	AY 2013-14	Income Tax Appellate Tribunal
Income Tax Act, 1961	Income Tax and interest thereon	4,680.71	-	AY 2014-15	Income Tax Appellate Tribunal
Income Tax Act, 1961	Income Tax and interest thereon	2,201.69	2,201.69	AY 2015-16	Commissioner of Income Tax (Appeals)
Income Tax Act, 1961	Income Tax and interest thereon	1,704.29	1,704.29	AY 2016-17	Commissioner of Income Tax (Appeals)
Income Tax Act, 1961	Income Tax and interest thereon	4,355.63	4,355.63	AY 2017-18	Commissioner of Income Tax (Appeals)

Annexure A to the Independent Auditor's Report on the Financial Statements of International Hospital Limited for the year ended 31 March 2026 (Continued)

Name of the statute	Nature of the dues	Amount (Rs. in lacs)	Amount Paid under protest (Rs. in lacs)	Period to which the amount relates	Forum where dispute is pending
Income Tax Act, 1961	Income Tax and interest thereon	18,735.23	10,041.93	AY 2018-19	Commissioner of Income Tax (Appeals)
Income Tax Act, 1961	Income Tax and interest thereon	7,619.14	-	AY 2019-20	Commissioner of Income Tax (Appeals)
Haryana Value Added Tax Act, 2003	Value Added Tax	312.56	-	FY 2007-08	Hon'ble Supreme Court of India
Haryana Value Added Tax Act, 2003	Value Added Tax	412.59	-	FY 2008-09	Hon'ble Supreme Court of India
Haryana Value Added Tax Act, 2003	Value Added Tax	259.11	-	FY 2009-10	Hon'ble Supreme Court of India
Haryana Value Added Tax Act, 2003	Value Added Tax	496.35	-	FY 2010-11	Hon'ble Supreme Court of India
The Uttar Pradesh Value Added Tax Act 2008	Value Added tax and Interest thereon	188.65	-	FY 2013-14, FY 2014-15, FY 2016-17 and FY 2017-18	Additional. Commissioner (Appeals) - Noida
The Uttar Pradesh Value Added Tax Act 2008	Value Added tax and Interest thereon	477.00	477.00	FY 2015-16	Hon'ble High Court of Allahabad
The Maharashtra Value Added Tax Act, 2002	Value Added tax and Interest thereon	20.19	0.89	FY 2015-16	Joint Commissioner - VAT Maharashtra
The West Bengal Value Added Tax Act, 2003	Value Added tax and Interest thereon	1,230.53	63.73	April'2017 to June'2017	Joint Commissioner - VAT West Bengal
The Central Goods and Services Act, 2017	Goods and services tax	30.41	-	April'2020 to Mar'2021	GST Appellate Authority

Annexure A to the Independent Auditor's Report on the Financial Statements of International Hospital Limited for the year ended 31 March 2026 (Continued)

Name of the statute	Nature of the dues	Amount (Rs. in lacs)	Amount Paid under protest (Rs. in lacs)	Period to which the amount relates	Forum where dispute is pending
The Central Goods and Services Act, 2017	Goods and services tax	3.66	0.17	2017-18	GST Appellate Authority
Finance Act, 1994	Service Tax	1,097.59	82.32	FY 2012-13 to June 2017	Customs Excise and Service Tax Appellate Tribunal (CESTAT)
Finance Act, 1994	Service Tax	1,144.72	42.93	01 Oct 2016 to 30 June 2017	Customs Excise and Service Tax Appellate Tribunal (CESTAT)
Employees Provident Fund & Miscellaneous Provisions Act, 1952	Provident fund and allied dues	94.97	-	FY 2014-15 to 2018-19	Employees Provident fund Appellate Tribunal, Delhi-CGIT, Rouse Avenue, Delhi
The India Stamp Act, 1899	Stamp duty and penalty thereon	51.87	-	FY 2011-12	Chief Controlling Revenue authority, Board of Revenue, Allahabad

(viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

(ix) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans and borrowing or in the payment of interest thereon to banks or financial institutions or any other lender, except those mentioned below:

Nature of borrowing including debt securities	Name of lender	Amount not paid on due date (Rupees in lacs)	Whether principal or interest	No. of days delay or unpaid	Remarks, if any
Non-Convertible Debentures	Fortis Healthcare Limited	4,667.36	Interest	127 to 2,717 days	Not paid till reporting date

Annexure A to the Independent Auditor’s Report on the Financial Statements of International Hospital Limited for the year ended 31 March 2026 (Continued)

Nature of borrowing including debt securities	Name of lender	Amount not paid on due date (Rupees in lacs)	Whether principal or interest	No. of days delay or unpaid	Remarks, if any
Optionally Convertible Debentures	Escorts Heart and Super Speciality Hospital Limited	2,649.45	Interest	48 to 656 days	Not paid till reporting date

Also refer note 9 of the financial statements.

The Company did not have any loans or borrowings from financial institutions or Government during the year.

- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority.
- (c) In our opinion and according to the information and explanations given to us by the management, term loans were applied for the purpose for which the loans were obtained.
- (d) According to the information and explanations given to us and on an overall examination of the financial statements of the Company, we report that no funds raised on short-term basis have been used for long-term purposes by the Company.
- (e) According to the information and explanations given to us and on an overall examination of the financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures as defined under the Act.
- (f) According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies (as defined under the Act).
- (x) (a) The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments). Accordingly, clause 3(x)(a) of the Order is not applicable.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.
- (xi) (a) During the course of our examination of the books and records of the Company and according to the information and explanations given to us, considering the principles of materiality outlined in Standards on Auditing, we report that no fraud by the Company or on the Company has been noticed or reported during the year.
- (b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Act has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- (c) We have taken into consideration the whistle blower complaints received by the Company during the year while determining the nature, timing and extent of our audit procedures.
- (xii) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.

Annexure A to the Independent Auditor's Report on the Financial Statements of International Hospital Limited for the year ended 31 March 2026 (Continued)

- (xiii) In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Section 177 and 188 of the Act, where applicable, and the details of the related party transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- (xiv) (a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has an internal audit system commensurate with the size and nature of its business.
- (b) We have considered the internal audit reports of the Company issued till date for the period under audit.
- (xv) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Act are not applicable to the Company.
- (xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.
- (b) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.
- (c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.
- (d) According to the information and explanations provided to us, there is no core investment company within the Group (as defined in the regulations made by the Reserve Bank of India). Accordingly, clause 3(xvi)(d) of the Order is not applicable. We have not, however, separately evaluated whether the information provided by the management is accurate and complete.
- (xvii) The Company has not incurred cash losses in the current and in the immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.
- (xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

Annexure A to the Independent Auditor's Report on the Financial Statements of International Hospital Limited for the year ended 31 March 2026 (Continued)

- (xx) In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of Section 135 of the Act pursuant to any project. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Rakesh Dewan

Partner

Place: Gurugram

Membership No.: 092212

Date: 18 May 2026

ICAI UDIN:26092212ZNHUFY9505

Annexure B to the Independent Auditor's Report on the financial statements of International Hospital Limited for the year ended 31 March 2026

Report on the internal financial controls with reference to the aforesaid financial statements under Clause (i) of Sub-section 3 of Section 143 of the Act

(Referred to in paragraph 2(A)(g) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Opinion

We have audited the internal financial controls with reference to financial statements of International Hospital Limited ("the Company") as of 31 March 2026 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such internal financial controls were operating effectively as at 31 March 2026, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

Management's and Board of Directors' Responsibilities for Internal Financial Controls

The Company's Management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Annexure B to the Independent Auditor's Report on the financial statements of International Hospital Limited for the year ended 31 March 2026 (Continued)

Meaning of Internal Financial Controls with Reference to Financial Statements

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Financial Statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Rakesh Dewan

Partner

Place: Gurugram

Membership No.: 092212

Date: 18 May 2026

ICAI UDIN:26092212ZNHUFY9505

INTERNATIONAL HOSPITAL LIMITED
BALANCE SHEET AS AT MARCH 31, 2026

Particulars	Notes	As at March 31, 2026 (Amount in ₹ lacs)	As at March 31, 2025 (Amount in ₹ lacs) (Restated)*
ASSETS			
A. Non-current assets			
(a) Property, plant and equipment	5(i)(a)	161,696.23	124,675.93
(b) Capital work-in-progress	5(i)(b)	12,060.46	26,771.20
(c) Right-of-use assets	7(a)	46,134.46	8,209.56
(d) Goodwill	5(ii)	24,313.85	24,313.85
(e) Other intangible assets	5(iii)(a)	493.90	553.24
(f) Intangible assets under development	5(iii)(b)	142.13	158.13
(g) Financial assets			
(i) Investments	5(iv)	177,265.79	145,230.63
(ii) Loans	5(vi)	-	120.00
(iii) Other financial assets	5(vii)	3,976.51	1,090.08
(h) Non-current tax assets (net)	5(ix)	27,440.34	26,330.31
(i) Other non-current assets	5(x)	1,367.66	1,156.64
Total non-current assets (A)		454,891.33	358,609.57
B. Current assets			
(a) Inventories	5(xi)	2,918.40	2,241.56
(b) Financial assets			
(i) Trade receivables	5(v)	34,224.94	26,579.38
(ii) Cash and cash equivalents	5(xii)(a)	1,066.55	194.06
(iii) Bank balances other than (iii) above	5(xii)(b)	46.01	86.00
(iv) Other financial assets	5(vii)	2,994.36	35,673.57
(c) Other current assets	5(x)	1,458.06	1,434.87
Total current assets (B)		42,708.32	66,209.45
Total assets (A+B)		497,599.65	424,819.02
EQUITY AND LIABILITIES			
A. Equity			
(a) Equity share capital	5(xiii)	87,948.90	87,948.90
(b) Instruments entirely equity in nature	5(xiii)	1,047.68	1,047.68
(c) Other equity		150,035.28	119,781.12
Total equity (A)		239,031.86	208,777.70
Liabilities			
B. Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	5(xv)	71,056.28	64,278.90
(ii) Lease liabilities	7(a)	34,212.48	1,108.40
(iii) Other financial liabilities	5(xvi)	36,345.62	31,339.83
(b) Provisions	5(xvii)	5,214.15	4,003.76
(c) Deferred tax liabilities (net)	5(viii)	16,046.72	14,677.73
(d) Other non-current liabilities	5(xix)	7.50	21.42
Total non-current liabilities (B)		162,882.75	115,430.04
C. Current liabilities			
(a) Financial liabilities			
(i) Borrowings	5(xv)	47,311.45	46,714.35
(ii) Trade payables	5(xviii)		
Total outstanding dues of micro enterprises and small enterprises; and		2,178.39	2,430.37
Total outstanding dues of creditors other than micro enterprises and small enterprises		25,069.96	19,122.80
(iii) Lease liabilities	7(a)	621.07	326.43
(iv) Other financial liabilities	5(xvi)	15,606.37	27,101.37
(b) Provisions	5(xvii)	703.47	581.98
(c) Other current liabilities	5(xix)	4,194.33	4,333.98
Total current liabilities (C)		95,685.04	100,611.28
Total liabilities (B+C)		258,567.79	216,041.32
Total equity and liabilities (A+B+C)		497,599.65	424,819.02

*refer note 24

See accompanying notes forming part of the financial
In terms of our report attached

1-24

For **B S R & Co. LLP**
Chartered Accountants
Firm Registration Number: 101248W/W-100022

For and on behalf of the Board of Directors
International Hospital Limited

Rakesh Dewan
Partner
Membership Number: 092212

Dr. Ananth Rao Nanjunda
Whole time Director
DIN: 11395535

Anil Vinayak
Director
DIN: 02407380

Place : Gurugram
Date : May 18, 2026

Satyendra Chauhan
Company Secretary
Membership No.: 14783
Place : Gurugram
Date : May 18, 2026

Ravi Bhatia
Chief Financial Officer

INTERNATIONAL HOSPITAL LIMITED
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2026

	Notes	Year ended March 31, 2026 (Amount in ₹ lacs)	Year ended March 31, 2025 (Amount in ₹ lacs) (Restated)*	
I	Revenue from operations	5(xx)	248,394.72	208,298.51
II	Other income	5(xxi)	5,168.74	9,833.58
III	Total income (I+II)		253,563.46	218,132.09
IV	Expenses			
	i) Purchase of medical consumable and drugs		51,739.24	43,602.23
	ii) Changes in inventories of medical consumable and drugs	5(xxii)	(676.84)	(192.53)
	iii) Employee benefits expense	5(xxiii)	27,527.27	23,946.48
	iv) Finance costs	5(xxiv)	15,861.88	15,454.04
	v) Depreciation and amortisation expense	5(xxv)	10,623.51	7,964.29
	vi) Other expenses	5(xxvi)	106,868.58	88,373.07
	Total expenses (IV)		211,943.64	179,147.58
V	Profit before exceptional and tax item (III-IV)		41,619.82	38,984.51
VI	Exceptional Item	5(xxvii)	(1,081.63)	(3,770.80)
VII	Profit before tax (V+VI)		40,538.19	35,213.71
VIII	Tax expense	5(xxviii)		
	i) Current tax		8,911.37	5,351.58
	ii) Deferred tax charge		1,369.92	3,163.08
	Total tax expense (VIII)		10,281.29	8,514.67
IX	Profit for the year (VII-VIII)		30,256.90	26,699.04
	Other comprehensive income			
	i) Items that will not be reclassified to profit or loss			
	(a) Remeasurements of the defined benefit liabilities		(3.66)	(265.89)
	(b) Income tax relating to items that will not be reclassified to profit or loss		0.92	66.92
X	Total other comprehensive loss for the year (net of tax)		(2.74)	(198.97)
XI	Total comprehensive income for the year (IX+X)		30,254.16	26,500.07
	Earnings per equity share of Rupees 100 each:			
	i) Basic (in ₹)	5(xxix)	30.74	27.13
	ii) Diluted (in ₹)	5(xxix)	30.74	27.13

*refer note 24

See accompanying notes forming part of the financial statements

1-24

In terms of our report attached

For **B S R & Co. LLP**
Chartered Accountants
Firm Registration Number: 101248W/W-100022

For and on behalf of the Board of Directors
International Hospital Limited

Rakesh Dewan
Partner
Membership Number: 092212

Dr. Ananth Rao Nanjunda
Whole time Director
DIN: 11395535

Anil Vinayak
Director
DIN: 02407380

Place : Gurugram
Date : May 18, 2026

Satyendra Chauhan
Company Secretary
Membership No.: 14783

Ravi Bhatia
Chief Financial Officer

Place : Gurugram
Date : May 18, 2026

INTERNATIONAL HOSPITAL LIMITED
STATEMENT OF CASH FLOW FOR THE YEAR ENDED MARCH 31, 2026

	Year ended March 31, 2026 (Amount in ₹ lacs)	Year ended March 31, 2025 (Amount in ₹ lacs) (Restated)*
Cash flows from operating activities		
Profit before tax	40,538.19	35,213.71
Adjustments for:		
Finance costs	15,861.88	15,454.04
Exceptional items	-	3,770.80
Interest income	(5,158.00)	(5,939.89)
Loss/ (profit) on sale of property, plant and equipment (net)	10.31	(3,893.38)
Allowance of allowance for doubtful trade receivables	1,434.89	1,287.41
Allowance for doubtful advances	141.19	110.94
Liabilities no longer required written back	(444.04)	(316.73)
Depreciation and amortisation expense	10,623.51	7,964.29
	63,007.93	53,651.19
Working capital adjustments		
(Increase)/decrease in trade and other receivables	(9,080.45)	965.19
Increase in inventories	(676.84)	(192.53)
Increase in other assets	(261.03)	(913.00)
Increase in financial assets	(10,097.23)	(5,541.62)
Increase in trade payables	6,139.16	2,028.44
Increase in financial liabilities	171.44	273.85
Increase in provisions	1,030.24	580.06
(Decrease) / increase in other liabilities	(153.57)	307.91
Cash generated from operating activities	50,079.65	51,159.49
Income taxes paid (net)	(10,021.34)	(8,465.82)
Net cash generated by operating activities	40,058.31	42,693.67
Cash flows used in investing activities		
Proceeds from disposal of property, plant and equipment	342.10	11,931.49
Purchase of property, plant and equipment and intangible asset	(33,818.26)	(24,103.28)
Proceeds from maturity in bank deposits (net)	39.99	6,796.96
Investment made in equity shares (refer note 5(iv)(b))	(27,225.75)	-
Interest received	420.28	569.29
Amount received from related party (refer note 5(vii))	35,466.42	-
Repayment of loan by Subsidiary	120.00	-
Net cash used in investing activities	(24,655.22)	(4,805.54)
Cash flows used in financing activities		
Proceeds from non-current borrowings	19,659.49	77.08
Repayment of non-current borrowings	(12,289.82)	(3,886.33)
Repayment from current borrowings	-	(19,873.93)
Principal repayment of lease liabilities	(443.27)	(333.32)
Interest paid #	(21,461.81)	(13,635.89)
Net cash used in financing activities	(14,535.41)	(37,652.39)
Net increase in cash and cash equivalents	867.68	235.74
Cash and cash equivalents at the beginning of the year	(552.36)	(788.10)
Cash and cash equivalents at the end of the year (refer note 5(xii)(a))	315.32	(552.36)
Bank overdrafts (refer note 5(xv))	751.23	746.42
Cash and cash equivalents as per statement of balance sheet	1,066.55	194.06

#Including interest on lease liabilities Rupees 1,744.55 lacs and Rupees 146.48 lacs for the year ended March 31, 2026 and March 31, 2025 respectively

Notes:

(a) The statement of cash flow has been prepared in accordance with "Indirect Method" as set out on Indian Accounting Standard -7 on "Statement on Cash flows"

(b) The Company has paid ₹ 511.37 lacs for the year ended March 31, 2026 and ₹ 309.77 lacs for the year ended March 31, 2025 towards Corporate Social Responsibility (CSR) expenditure.

* refer note 24

See accompanying notes forming part of the financial statements

1-24

In terms of our report attached

For **B S R & Co. LLP**
Chartered Accountants

Firm Registration Number: 101248W/W-100022

For and on behalf of the Board of Directors
International Hospital Limited

Rakesh Dewan
Partner

Membership Number: 092212

Dr. Ananth Rao Nanjunda
Whole time Director

DIN: 11395535

Anil Vinayak
Director

DIN: 02407380

Place : Gurugram
Date : May 18, 2026

Satyendra Chauhan
Company Secretary
Membership No.: 14783

Ravi Bhatia
Chief Financial Officer

Place : Gurugram
Date : May 18, 2026

INTERNATIONAL HOSPITAL LIMITED
STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED MARCH 31, 2026

Particular	Equity		Other equity				(Amount in ₹ lacs)	
	Equity share capital	Compulsory convertible non participating preference share	Reserves and Surplus				Total other equity	Total
			Securities premium*	Capital redemption reserve	Retained earnings	Demerger Deficit Reserve**		
Balance at April 01, 2024 (refer note 24)	87,948.90	1,047.68	78,532.80	46.00	69,735.70	(55,033.45)	93,281.05	182,277.63
Profit for the year	-	-	-	-	26,699.04	-	26,699.04	26,699.04
Other comprehensive loss for the year (net of income tax)	-	-	-	-	(198.97)	-	(198.97)	(198.97)
Total comprehensive income for the year	-	-	-	-	26,500.07	-	26,500.07	26,500.07
Balance at March 31, 2025	87,948.90	1,047.68	78,532.80	46.00	96,235.77	(55,033.45)	119,781.12	208,777.70
Profit for the year	-	-	-	-	30,256.90	-	30,256.90	30,256.90
Other comprehensive loss for the year (net of income tax)	-	-	-	-	(2.74)	-	(2.74)	(2.74)
Total comprehensive income for the year	-	-	-	-	30,254.16	-	30,254.16	30,254.16
Balance at March 31, 2026	87,948.90	1,047.68	78,532.80	46.00	126,489.93	(55,033.45)	150,035.28	239,031.86

* The unutilized accumulated excess of issue price over face value on issue of shares. This reserve is utilised in accordance with the provisions of the Companies Act 2013.

** Reserve created as per composite scheme of arrangement (refer note 24)

See accompanying notes forming part of the financial statements

1-24

In terms of our report attached

For **B S R & Co. LLP**
Chartered Accountants
Firm Registration Number: 101248W/W-100022

For and on behalf of the Board of Directors
International Hospital Limited

Rakesh Dewan
Partner
Membership Number: 092212

Dr. Ananth Rao Nanjunda
Whole time Director
DIN: 11395535

Anil Vinayak
Director
DIN: 02407380

Place : Gurugram
Date : May 18, 2026

Satyendra Chauhan
Company Secretary
Membership No.: 14783

Ravi Bhatia
Chief Financial Officer

Place : Gurugram
Date : May 18, 2026

INTERNATIONAL HOSPITAL LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED MARCH 31, 2026

1. Corporate Information

International Hospital Limited (“the Company”) (CIN: U74999HR1994PLC048225) was incorporated in India in the year 1994 and is a subsidiary of Fortis Healthcare Limited (FHL). The Company is engaged in the business of providing clinical establishment services including certain out-patient department (OPD) and radio diagnostic services at Bannerghatta Road (Bengaluru) and running hospital operations in Rajajinagar (Bengaluru), Kalyan, Amritsar, Faridabad, Kolkata (Anandpur), FHKI Kolkata, Noida, Greater Noida and Mulund. The ultimate holding company is IHH Healthcare Berhad. The Company has also entered into Hospital and Medical Services Agreements (HMSA) with Fortis Hospitals Limited (FHsL) and shall provide FHsL on an exclusive principal-to-principal basis, hospital services including clinical establishment services, OPD services and radio diagnostic services and shall receive service fee in respect thereof.

The registered office of the Company is located at Fortis Memorial Research Institute, Sector-44, Gurugram-122002, Haryana, India and the corporate office of the Company is located at Tower A, 3rd Floor, Unitech Business Park, Block – F, South City 1, Sector – 41, Gurugram, 122001, Haryana, India.

2. Material accounting policies

This note provides a list of the material accounting policies adopted in the preparation of these financial statements. The accounting policies adopted are consistent with those of the previous financial year.

(a) Basis of preparation

(i) Statement of compliance

These financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) as per the Companies (Indian Accounting Standards) Rules, 2015 as amended notified under Section 133 of Companies Act, 2013, (“the Act”) and other relevant provisions of the Act. All the amounts included in the financial statements are reported in lacs of Indian Rupees and are rounded to the nearest lac to two decimals, except per share data.

The financial statements have been authorized for issue by the Company’s Board of Directors on May 18, 2026.

(ii) Functional and presentation currency

These financial statements are presented in Indian Rupees (₹), which is also the Company’s functional currency.

(iii) Basis of measurement

The financial statements have been prepared under historical cost convention on accrual basis except for the following items:

Item basis	Measurement
Net defined benefit (asset)/ liability	Fair value of plan assets less the present value of the defined benefit obligation
Derivative assets	Fair Value

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

(iv) Consolidated financial statements

The Company has opted for exemption from preparation of consolidated financial statements under Rule 6 of the Companies (Accounts) Rules, 2014, as amended, and accordingly prepared only standalone financial statements.

INTERNATIONAL HOSPITAL LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED MARCH 31, 2026

(b) Current versus non-current classification

Based on the time involved between the acquisition of assets for processing and their realization in cash and cash equivalents, the Company has identified twelve months as its operating cycle for determining current and non-current classification of assets and liabilities in the balance sheet.

The Company shall classify a liability as current when:

- a. it expects to settle the liability in its normal operating cycle.
- b. it holds the liability primarily for the purpose of trading.
- c. the liability is due to be settled within twelve months after the reporting period; or
- d. it does not have the right at the end of the reporting period to defer settlement of the liability for at least twelve months after the reporting period.

The Company shall classify all other liabilities as non-current.

(c) Measurement of fair values

A number of the accounting policies and disclosures require measurement of fair values, for both financial and non-financial assets and liabilities. Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Company has an established control framework with respect to the measurement of fair values. This includes a finance team that has overall responsibility for overseeing all significant fair value measurements, including Level 3 fair values.

When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement. The Company recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

(d) Property, plant and equipment (PPE) and intangible assets

(i) Property, plant and equipment

The cost of an item of property, plant and equipment shall be recognised as an asset if, and only if it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably.

Freehold land is carried at cost. All other items of property, plant and equipment are stated at cost, which includes capitalized borrowing costs, less accumulated depreciation and any accumulated impairment loss. The cost of an item of Property, Plant and Equipment comprises its purchase price, including import duties and other non-refundable taxes or levies, freight, any directly attributable cost of bringing the asset to its working condition for its intended use and estimated cost of dismantling and restoring onsite; any trade discounts and rebates are deducted in arriving at the purchase price.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.

Advances paid towards acquisition of property, plant and equipment outstanding at each Balance Sheet date, are shown under other non-current assets and cost of assets not ready for intended use before the year end, are shown as capital work-in-progress.

INTERNATIONAL HOSPITAL LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED MARCH 31, 2026

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major Components) of property, plant and equipment.

(ii) Goodwill and other intangible assets

a) Recognition and measurement

- For measurement of goodwill that arises from business combination, refer note 2(e). Subsequent measurement is at cost less any accumulated impairment losses.
- Internally generated goodwill is not recognised as an asset. With regard to other internally generated intangible assets:
 - Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognised in the statement of profit and loss as incurred.
 - Development expenditure including regulatory cost and legal expenses leading to product registration/market authorisation relating to the new and/or improved product and/or process development is capitalised only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use the asset. The expenditure capitalised includes the cost of materials, direct labour, overhead costs that are directly attributable to preparing the asset for its intended use, and directly attributable borrowing costs (in the same manner as in the case of property, plant and equipment). Other development expenditure is recognised in the Statement of Profit and Loss as incurred.
- Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is recognised at fair value at the date of acquisition. An intangible asset is recognised only if it is probable that future economic benefits attributable to the asset will flow to the Company and the cost of the asset can be measured reliably. After initial recognition, other intangible assets, including those required by the Company in a business combination and have finite lives are measured at cost less accumulated amortization and any accumulated impairment loss.

b) Subsequent expenditure

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates and the cost of the asset can be measured reliably. All other expenditure, including expenditure on internally generated goodwill and brands, is recognised in profit or loss as incurred.

c) Amortisation

Amortisation is calculated to write off the cost of intangible assets less their estimated residual values using the straight-line method over their estimated useful lives and is generally recognised in depreciation and amortisation in Statement of profit and loss. Goodwill is not amortised.

Amortisation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

(iii) Depreciation and amortization methods, estimated useful lives and residual value

Depreciation is provided on straight line basis on the original cost/ acquisition cost of assets or other amounts substituted for cost of property, plant and equipment as per the useful life specified in Part 'C' of Schedule II of the Act, read with notification dated 29 August 2014 of the Ministry of Corporate Affairs, except for the certain classes of property, plant and equipment which are depreciated based on the internal technical assessment of the management. The details of useful life are as under:

Category of assets	Management estimate of useful life	Useful life as per Schedule II
Buildings	10-60 years	60 years
Plant & Machinery	15-20 years	15 years
Medical Equipment	8-16 years	13 years
Computers	3-6 years	3 years

INTERNATIONAL HOSPITAL LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED MARCH 31, 2026

Furniture and fixtures	4-16 years	10 years
Category of assets	Management estimate of useful life	Useful life as per Schedule II
Office equipment	4-5 years	5 years
Leasehold improvement	4-8 years	8 years

Freehold land is not depreciated.

Depreciation on leasehold assets is provided over the lease term or expected useful life of the asset, whichever is lower.

Goodwill is not amortized and is tested for impairment annually or more frequently if events or changes in circumstances indicate that they might be impaired. Estimated useful lives of the other intangible assets are as follows:

Category of assets	Management estimate of useful life
Computer software	3-6 years
License fee	3-10 years

Depreciation and amortization on property, plant and equipment and intangible assets added/disposed off during the year has been provided on pro-rata basis with reference to the date/month of addition/disposal.

Depreciation and amortization methods, useful lives and residual values are reviewed at the end of each reporting period and adjusted if appropriate.

(iv) Derecognition

A property, plant and equipment and intangible assets is derecognized on disposal or when no future economic benefits are expected from its use and disposal. Losses arising from retirement and gains or losses arising from disposal of a tangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the Statement of Profit and Loss.

(e) Impairment of non-financial assets

Goodwill and other intangible assets that have an indefinite useful life are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. The Company's non-financial assets other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

For impairment testing, assets that do not generate independent cash inflows (i.e. corporate assets) are companied together into cash-generating units (CGUs). Each CGU represents the smallest company of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU.

An impairment loss is recognised if the carrying amount of an asset or CGU exceeds its estimated recoverable amount. Impairment loss recognized in respect of a CGU is allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amount of the other assets of the CGU (or company of CGUs) on a pro rata basis.

An impairment loss in respect of goodwill is not subsequently reversed. In respect of other assets for which impairment loss has been recognized in prior periods, the Company reviews at reporting date whether there is any indication that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. Such a reversal is made only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

INTERNATIONAL HOSPITAL LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED MARCH 31, 2026

(f) Financial instrument

A Financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Initial recognition and measurement

Trade receivables and debt securities issued are initially recognised when they are originated. All other financial assets and financial liabilities are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

A financial asset (unless it is a trade receivable without a significant financing component) or financial liability is initially measured at fair value plus or minus, for an item not at FVTPL, transaction costs that are directly attributable to its acquisition or issue. A trade receivable without a significant financing component is initially measured at the transaction price.

Financial assets

Initial recognition and measurement

All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the marketplace (regular way trades) are recognised on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

Subsequent measurement

For purposes of subsequent measurement, financial assets are classified in four categories:

- Debt instruments at amortised cost
- Debt instruments at fair value through other comprehensive income (FVOCI)
- Debt instruments, derivatives and equity instruments at fair value through profit or loss (FVPL)
- Equity instruments measured at fair value through other comprehensive income (FVOCI)

Debt instruments at amortised cost

A 'debt instrument' is measured at the amortised cost if the asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. The effective interest rate is the rate that exactly discounts estimated future cash payments or receipts through the expected life of the financial instrument to the gross carrying amount of the financial asset or the amortised cost of the financial liability. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included in other income in the Statement of Profit and Loss. The losses arising from impairment are recognised in the Statement of Profit and Loss. This category generally applies to trade and other receivables.

Debt instrument at FVOCI

A 'debt instrument' is classified as at the FVOCI if the objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets, and the asset's contractual cash flows represent SPPI.

Debt instruments included within the FVOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognised in the other comprehensive income (OCI). On derecognition of the asset, cumulative gain or loss previously recognised in OCI is reclassified to the Statement of Profit and Loss. Interest earned whilst holding FVOCI debt instrument is reported as interest income using the EIR method.

INTERNATIONAL HOSPITAL LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED MARCH 31, 2026

Debt instrument at FVPL

FVPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVOCI, is classified as at FVPL. In addition, at initial recognition, the Company may irrevocably elect to designate a debt instrument, which otherwise meets amortised cost or FVOCI criteria, as at FVPL. However, such election is allowed only if doing so reduces or eliminates a measurement or recognition inconsistency (referred to as 'accounting mismatch').

Debt instruments included within the FVPL category are measured at fair value with all changes recognised in the Statement of Profit and Loss.

Equity investments

Equity investments in subsidiaries and associates are carried at cost less accumulated impairment losses, if any. Where an indication of impairment exists, the carrying amount of the investment is assessed and written down immediately to its recoverable amount. On disposal of investments in such entities, the difference between net disposal proceeds and the carrying amounts are recognized in the Statement of Profit and Loss.

All other equity investments which are in scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading and contingent consideration recognised by an acquirer in a business combination to which Ind AS 103 applies are classified as at FVPL. For all other equity instruments in scope of Ind AS 109, the Company may make an irrevocable election to present in other comprehensive income subsequent changes in the fair value. The Company makes such election on an instrument-by-instrument basis. The classification is made on initial recognition and is irrevocable.

If the Company decides to classify an equity instrument as at FVOCI, then all fair value changes on the instrument, excluding dividends, are recognised in the OCI. There is no recycling of the amounts from OCI to the Statement of Profit and Loss, even on sale of investment. However, the Company may transfer the cumulative gain or loss to retained earnings.

Equity instruments included within the FVPL category are measured at fair value with all changes recognised in the Statement of Profit and Loss.

Impairment of financial assets

The Company recognizes loss allowance using the expected credit loss (ECL) model for the financial assets which are not fair valued through profit or loss. Loss allowance for trade receivables with no significant financing component is measured at an amount equal to lifetime ECL. For all financial assets with contractual cash flows other than trade receivable, ECLs are measured at an amount equal to the 12-month ECL, unless there has been a significant increase in credit risk from initial recognition in which case those are measured at lifetime ECL. The amount of ECL (or reversal) that is required to adjust the loss allowance at the reporting date is recognized as an impairment gain or loss in the Statement of Profit and Loss.

Credit-impaired financial assets

At each reporting date, the Company assesses whether financial assets carried at amortised cost and debt securities at FVOCI are credit-impaired. A financial asset is 'credit-impaired' when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred. Evidence that a financial asset is credit-impaired includes the following observable data:

- significant financial difficulty of the debtor;
- a breach of contract such as a default;
- the restructuring of a loan or advance by the Company on terms that the Company would not consider otherwise;
- it is probable that the debtor will enter bankruptcy or other financial reorganisation; or
- the disappearance of an active market for a security because of financial difficulties.

Presentation of allowance for ECL in the balance sheet

Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount of the assets.

INTERNATIONAL HOSPITAL LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED MARCH 31, 2026

Derecognition of financial assets

A financial asset (or, where applicable, a part of a financial asset or part of a company of similar financial assets) is primarily derecognized (i.e., removed from the Company's balance sheet) when:

- The rights to receive cash flows from the asset have expired, or
- The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognize the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

Write-off of financial assets

The gross carrying amount of a financial asset is written off when the Company has no reasonable expectations of recovering a financial asset in its entirety or a portion thereof. The Company expects no significant recovery from the amount written off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Company's procedures for recovery of amounts due.

Financial liabilities

Financial liabilities are classified as measured at amortised cost or FVPL. A financial liability is classified as at FVPL if it is classified as held-for-trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVPL are measured at fair value and net gains and losses, including any interest expense, are recognised in Statement of Profit and Loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in Statement of Profit and Loss. Any gain or loss on derecognition is also recognized in Statement of Profit and Loss.

Derecognition of financial liabilities

A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the Statement of Profit and Loss.

Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the Balance Sheet when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously.

(g) Cash and cash equivalents

Cash and cash equivalents include cash in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less.

For the purpose of cash flow statement, cash and cash equivalent includes cash in hand, in banks, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less, net of outstanding bank overdrafts that are repayable on demand and are considered part of the cash management system.

INTERNATIONAL HOSPITAL LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED MARCH 31, 2026

(h) Contingent liabilities and contingent assets

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize a contingent liability but discloses its existence in the financial statements unless the possibility of an outflow of resources embodying economic benefits is remote. Contingent liabilities and commitments are reviewed by the management at each balance sheet date.

Contingent assets are not recognised in the financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognised in the period in which the change occurs.

(i) Provisions

A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a borrowing cost.

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at reporting date, taking into account the risks and uncertainties surrounding the obligation. When some or all the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognized as an asset if it is virtually certain that reimbursement will be received, and the amount of the receivable can be measured reliably.

A contract is considered to be onerous when the expected economic benefits to be derived by the Company from the contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision for an onerous contract is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before such a provision is made, the Company recognizes any impairment loss on the assets associated with that contract.

Provisions are reviewed at each balance sheet date and adjusted to reflect the current best estimate. If it is no longer probable that the outflow of resources would be required to settle the obligation, the provision is reversed.

(j) Government grant

The Company recognize government grant that compensate the Company for expenses in profit or loss on a systematic basis in the periods in which the expenses are recognised, unless the conditions for receiving the grant are met after the related expenses have been recognised. The grant is recognised when it becomes receivable and adjusted against relevant expenses in the statement of profit and loss.

(k) Revenue recognition

Revenue in patient hospital services and Management fees from hospitals is recognised over the period of time, as and when services are performed. Revenue from outpatient hospital services is recognised at a point in time when patient has actually received the service. Revenue from sale of products is recognised at the point in time upon transfer of control of products to customers at the time of delivery of goods to the customers.

Revenue from Hospital and Medical Service which is recognised as and when services are rendered. As per Hospital and Medical Services Agreement (HMSA), total operating income is bifurcated into base fees (which is fixed) and variable fees (which is fixed percentage of actual revenue earned by the hospital operating companies).

Contracts with customers could include promises to transfer multiple services/ products to a customer. The Company assesses the product/ services promised in a contract and identifies distinct performance obligation in the contract. Revenue towards satisfaction of a performance obligation is measured at the amount of transaction price (net of variable consideration) allocated to that performance obligation. The transaction price of services rendered and goods sold if net of variable consideration on account of various discounts and schemes offered by the Company as part of the

INTERNATIONAL HOSPITAL LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED MARCH 31, 2026

contract including claims. Revenue for each distinct performance obligation is measured to at an amount that reflects the consideration which the Company expects to receive in exchange for those products or services and is net of tax collected from customers and remitted to government authorities such as sales tax, excise duty, value added tax and applicable discounts and allowances including claims. Further, the Company also determines whether the performance obligation is satisfied at a point in time or over a period of time. These judgments and estimations are based on various factors including contractual terms and historical experience.

Revenue includes only those sales for which the Company has acted as a principal in the transaction, takes title to the products, and has the risks and rewards of ownership, including the risk of loss for collection, delivery and returns. Any revenue transaction for which the Company has acted as an agent or broker without assuming the risks and rewards of ownership have been reported on a net basis.

Excess of revenue earned over billings on contracts is recognised as unbilled revenue. Unbilled revenue is classified as trade receivables when there is unconditional right to receive cash, and only passage of time is required, as per contractual terms. Unearned and deferred revenue is recognised as other current liability when there are billings in excess of revenues.

Other operating revenue comprises revenue from rental income which is recognised in accordance with terms of agreements entered into with the respective lessees.

(I) Employee benefits

Short-term employee benefits

All employee benefits falling due within twelve months of the end of the period in which the employees render the related services are classified as short-term employee benefits, which include benefits like salaries, wages, short term compensated absences, performance incentives, etc. and are recognised as expenses in the period in which the employee renders the related service and measured accordingly. Short term employee benefits are measured on an undiscounted basis.

Post-employment benefits

Post-employment benefit plans are classified into defined benefits plans and defined contribution plans as under:

a) Gratuity

The Company has an obligation towards gratuity, a defined benefit retirement plan covering eligible employees. The plan provides for a lump sum payment to vested employees at retirement, death while in employment or on termination of employment of an amount based on the respective employee's salary and the tenure of employment. The liability in respect of gratuity is recognised in the books of account based on actuarial valuation by an independent actuary. The gratuity liability for certain employees of the Company is funded with Life Insurance Corporation of India.

b) Provident fund

The Company makes contribution to the Regional Provident Fund Commissioner in accordance with the provisions of the code of Social Security, 2020.

The Company's contribution to the provident fund is charged to Statement of Profit and Loss.

Other long-term employee benefits:

As per the Company's policy, eligible leaves can be accumulated by the employees and carried forward to future periods to either be utilized during the service, or encashed. Encashment can be made during service, on early retirement, on withdrawal of scheme, at resignation and upon death of the employee. Accumulated compensated absences are treated as other long-term employee benefits.

Termination benefits are recognised as an expense when, as a result of a past event, the Company has a present obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation.

INTERNATIONAL HOSPITAL LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED MARCH 31, 2026

Actuarial valuation

The liability in respect of all defined benefit plans and other long-term benefits is accrued in the books of account on the basis of actuarial valuation carried out by an independent actuary using the Projected Unit Credit Method. The obligation is measured at the present value of estimated future cash flows. The discount rates used for determining the present value of obligation under defined benefit plans, is based on the market yields on Government securities as at the Balance Sheet date, having maturity periods approximating to the terms of related obligations.

Remeasurement gains and losses on other long-term benefits are recognised in the Statement of Profit and Loss in the year in which they arise. Remeasurement gains and losses in respect of all defined benefit plans arising from experience adjustments and changes in actuarial assumptions are recognised in the period in which they occur, directly in other comprehensive income. They are recognized immediately in the Statement of Changes in Equity with a corresponding debit or credit to retained earnings through OCI in the period in which they occur. Changes in the present value of the defined benefit obligation resulting from plan amendments or curtailments are recognised immediately in profit or loss as past service cost. Gains or losses on the curtailment or settlement of any defined benefit plan are recognised when the curtailment or settlement occurs. Any differential between the plan assets (for a funded defined benefit plan) and the defined benefit obligation as per actuarial valuation is recognised as a liability if it is a deficit or as an asset if it is a surplus (to the extent of the lower of present value of any economic benefits available in the form of refunds from the plan or reduction in future contribution to the plan).

Past service cost is recognised as an expense in the Statement of Profit and Loss on a straight-line basis over the average period until the benefits become vested. To the extent that the benefits are already vested immediately following the introduction of, or changes to, a defined benefit plan, the past service cost is recognised immediately in the Statement of Profit and Loss. Past service cost may be either positive (where benefits are introduced or improved) or negative (where existing benefits are reduced).

(m) Borrowing costs

Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds including interest expense on lease liability. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs. General and specific borrowing costs that are directly attributable to the construction or production or development of a qualifying asset are capitalized as part of the cost of that asset. Qualifying assets are assets that necessarily take a substantial period of time to get ready for their intended use or sale. All other borrowing costs are expensed in the period in which they occur.

Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalization. Ancillary costs incurred in connection with the arrangement of borrowings are amortised over the period of such borrowings.

(n) Income tax

Income tax expense comprises current and deferred tax. It is recognised in Statement of Profit and Loss except to the extent that it relates to a business combination, or items recognised directly in equity or in OCI. Interest and penalties related to income taxes, including uncertain tax treatments, do not meet the definition of income taxes, and therefore accounted for them under Ind AS 37 Provisions, Contingent Liabilities and Contingent Assets.

Current taxes

Current tax comprises the best estimate of expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax payable or receivable is the best estimate of the tax amount expected to be paid or received after considering uncertainty related to income taxes, if any. It is measured using tax rates enacted or substantively enacted at the reporting date. Current tax assets and liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realize the asset and settle the liability on a net basis or simultaneously.

Deferred taxes

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is also recognized in respect of carried forward tax losses and tax credits. Deferred tax is not recognised for:

INTERNATIONAL HOSPITAL LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED MARCH 31, 2026

- temporary differences arising on the initial recognition of assets or liabilities in a transaction that
 - is not a business combination; and
 - at the time of transaction (i) affects neither accounting nor taxable profit or loss and (ii) does not give rise to equal taxable and deductible temporary differences;
- temporary differences related investments in fellow subsidiaries, associates and, to the extent that the Company is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future.

Deferred tax assets are recognised for unused tax losses, unused tax credits and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be used. Unrecognized deferred tax assets are reassessed at each reporting date and recognised to the extent that it has become probable that future taxable profits will be available against which they can be used. Deferred tax is measured at the tax rates that are expected to be applied to the period when the asset is realized or the liability is settled, based on the laws that have been enacted or substantively enacted by the reporting date. The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Company expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realize the asset and settle the liability on a net basis or simultaneously.

(o) Leases

At inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Company assesses whether:

- the contract involves the use of an identified asset – this may be specified explicitly or implicitly and should be physically distinct or represent substantially all of the capacity of a physically distinct asset. If the supplier has a substantive substitution right, then the asset is not identified;
- the Company has the right to obtain substantially all of the economic benefits from use of the asset through the period of use; and
- the Company has the right to direct the use of the asset. The Company has this right when it has the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In rare cases, where the decision about how and for what purpose the asset is used is predetermined, the Company has the right to direct the use of the asset if either:
 - the Company has the right to operate the asset; or
 - the Company designed the asset in a way that predetermines how and for what purpose it will be used

An entity shall reassess whether a contract is, or contains, a lease only if the terms and conditions of the contract are changed.

At inception or on reassessment of a contract that contains a lease component, the Company allocates the consideration in the contract to each lease component on the basis of their relative stand-alone prices.

(i) As a lessee

The Company accounts for assets taken under lease arrangement in the following manner:

The Company recognises a right-of-use asset and a lease liability at the lease commencement date. The right of use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentive received.

The right of use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. The estimated useful lives of right-of-use are determined on the same basis as those of property

INTERNATIONAL HOSPITAL LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED MARCH 31, 2026

and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the Company's incremental borrowing rate.

The Company determines its incremental borrowing rate by obtaining interest rates from various external financing sources and makes certain adjustments to reflect the terms of the lease and type of the asset leased.

Lease payments included in the measurement of the lease liability comprise the fixed payments, including in-substance fixed payments.

The lease liability is measured at amortised cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in Company's estimate of the amount expected to be payable under a residual value guarantee, or if the Company changes its assessment of whether it will exercise a purchase, extension or termination option.

When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.

Short-term leases and leases of low-value assets

The Company has elected not to recognise right-of-use assets and lease liabilities for short term leases that have a lease term of 12 months or less and leases of low value assets. The Company recognises the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

(ii) As a lessor

The Company accounts for assets given under lease arrangement in the following manner:

Leases in which a significant portion of the risks and rewards of ownership are not transferred to the Company as lessee are classified as operating leases. Assets subject to operating leases are included in property, plant and equipment. Rental income on operating lease is recognized in the Statement of Profit and Loss on a straight-line basis over the lease term.

Costs, including depreciation, are recognized as an expense in the Statement of Profit and Loss. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased assets and recognised on a straight-line basis over the lease term.

Leases are classified as finance leases when substantially all of the risks and rewards of ownership transfer from the Company to the lessee. Amounts due from lessees under finance leases are recorded as receivables at the Company's net investment in the leases. Finance lease income is allocated to accounting periods so as to reflect a constant periodic rate of return on the net investment outstanding in respect of the lease.

(p) Foreign currency translation

(i) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at balance sheet date exchange rates are generally recognised in Statement of Profit and Loss.

Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non-monetary assets such as equity investments classified as FVOCI are recognised in other comprehensive income (OCI).

INTERNATIONAL HOSPITAL LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED MARCH 31, 2026

(q) Statement of Cash flow

Cash flows are reported using the indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregate. The company considers all highly liquid investments that are readily convertible to known amounts of cash to be cash equivalents.

(r) Inventories

Inventories are valued at lower of cost or net realizable value except scrap, which is valued at net estimated realizable value.

The Company uses weighted average method to determine cost for all categories of inventories except for goods in transit which is valued at specifically identified purchase cost. Cost includes all costs of purchase, and other costs incurred in bringing the inventories to their present location and condition inclusive of non-refundable (adjustable) taxes wherever applicable.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs necessary to make the sale. The comparison of cost and net realizable value is made on an item-by-item basis.

(s) Operating segment

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Company's other components, and for which discrete financial information is available. Operating segments are reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker ("CODM"). Revenues, expenses, assets and liabilities, which are common to the enterprise as a whole and are not allocable to segments on a reasonable basis, have been treated as "unallocated revenues/ expenses/ assets/ liabilities", as the case may be.

The Company is primarily engaged in the business of healthcare services which is the only reportable segment

(t) Business combination under common control

Business combination involving companies in which all the combining companies are ultimately controlled by the same holding party, before and after the business combination and where such control is not transitory, are treated as per the pooling of interest method.

The pooling of interest method involves the following:

- (i) The assets and liabilities of the combining entities are reflected at their carrying amounts.
- (ii) No adjustments are made to reflect fair values or recognise any new assets or liabilities.
- (iii) The financial information in the financial statements in respect of prior periods are as if the business combination had occurred from the beginning of the preceding period in the financial statements, irrespective of the actual date of the combination.
- (iv) Inter-company balances and transactions held inter-se, if any between the transferor Company and the transferee Company in relation to the undertaking transferred, shall stand cancelled at the appointed date.
- (v) The identity of the reserves is preserved, and they appear in the financial statements of the Company in the same form in which they appeared in the financial statements of the demerged undertakings. The difference between the consideration and the value of net identifiable assets acquired is adjusted against the capital reserve or demerger deficit reserve (if debit).

(u) Earnings per share

- (i) Basic earnings per share

Basic earnings per share is calculated by dividing:

- the profit attributable to owners of the Company
- by the weighted average number of equity shares outstanding during the financial year, adjusted for bonus elements in equity shares and compulsory convertible shares issued during the year.

INTERNATIONAL HOSPITAL LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED MARCH 31, 2026

(ii) Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account:

- the after-income tax effect of interest and other financing costs associated with dilutive potential equity shares, and
- the weighted average number of additional equity shares that would have been outstanding assuming the conversion of all dilutive potential equity shares

(v) **Exceptional items**

On certain occasions, the size, type or incidence of an item of income or expense, pertaining to the ordinary activities of the Company is such that its disclosure improves the understanding of the performance of the Company. Such income or expense is classified as an exceptional item and accordingly disclosed in the financial statements.

3. Critical estimates and judgements

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Judgments

Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognized in the financial statements is included in the following notes:

a) Leasing arrangement (classification) – Note 7

b) PPE/ investment property- accounting for Hospital and Medical Service Agreements (“HMSA”)

Clinical establishment is defined as a fully centrally air-conditioned institution established and specifically customised and duly fitted with all fixtures, fittings, medical equipment and infrastructure required for running and operating a hospital, offering:

- doctors and services for diagnosis and treatment for illness, disease, injury, deformity and/or abnormality;
- diagnosis of diseases through radiological and other diagnostic or investigative services with the aid of laboratory or other medical equipment; and
- beds for in-patient treatment.

The Company has entered into Hospital and Medical Services Agreements ("HMSA") with Fortis Hospitals Limited wherein the Company is required to provide and maintain the Company's clinical establishment along with other services like out-patient diagnostic and radio diagnostic. The Company needs to exercise judgement to analyse whether the arrangement involves providing the right to use the Company's clinical establishment and whether the OPD and radio diagnostic services in the arrangement are significant to the overall arrangement.

The Company has analysed the substance of the contract and have determined that fulfilment of service arrangement is based on the use of specified assets and conveys right to use the Company's clinical establishments. However, substantial risk and rewards of the Company's clinical establishments are retained by the Company even though rights to use are given to hospital operating companies. The Company has assessed that the out-patient diagnostic and radio diagnostic services in the arrangement are significant to the entire arrangement. Consequently, the Company's clinical establishments have been classified as part of property, plant and equipment.

Assumptions and estimation uncertainties

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment is included in the following notes:

INTERNATIONAL HOSPITAL LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED MARCH 31, 2026

- Leasing arrangement (accounting) – Note 7
- Financial instruments - Note 11
- Fair value measurement – Note 12
- Assessment of useful life and residual value of property, plant and equipment and intangible asset – Note 2(d)(iii)
- Recognition of deferred tax assets: availability of future taxable profits against which deductible temporary differences and tax losses carried forward can be utilized – Note 5(xxviii) and 5(viii)
- Measurement of ECL allowance for trade receivables and other assets – Note 2(f)
- Estimation of assets and obligations relating to employee benefits (including actuarial assumptions) – Note 10
- Estimated impairment of financial assets and non-financial assets – Note 5(ii), 5(iv), 5 (vi), 5(vii)
- Recognition and measurement of contingency: Key assumption about the likelihood and magnitude of an outflow of resources – Note 16

4. Recent pronouncements

Ministry of Corporate Affairs (“MCA”) notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time.

A. Amendments effective during the year

In May 2025, MCA notified amendments to Ind AS 21 – The Effects of Changes in Foreign Exchange Rates, applicable w.e.f. April 1, 2025. The Company has reviewed the amendment and based on its evaluation has determined that it does not have any significant impact in its financial statements.

In August 2025, MCA notified the following amendment to:

- i. Ind AS 1, Presentation of Financial Statements, applicable w.e.f. April 1, 2025 –

The amendment relates to classification of liabilities as current or non-current and non-current liabilities with covenants. In the context of classifying a liability as current, it removes the requirement of existence of an unconditional right to defer settlement for at least 12 months after the reporting date, and instead requires that the said right should exist on the reporting date and have substance. The amendment also introduces guidance on classification of liabilities with covenants. The Company has no impact of these amendments in its classification criteria of current and non-current liabilities.

- ii. Ind AS 7, Statement of Cash Flows and Ind AS 107, Financial Instruments – Disclosures, applicable w.e.f. April 1, 2025 – The amendment in Ind AS 7 requires to inform users of financial statements of the existence of supplier finance arrangements and explain the nature of the arrangements, the carrying amount of liabilities and the range of payment due dates. Ind AS 107 has been amended to add supplier finance arrangements as a factor that may cause concentration of liquidity risk. The Company has not entered into any supplier finance arrangements and hence, does not impact any disclosure requirement.
- iii. Ind AS 12, International Tax Reform – Pillar Two Model Rules, applicable immediately - The amendments provide a temporary mandatory relief from deferred tax accounting for top-up tax and requires the Company to disclose that it has applied the relief. This relief is immediate and applies retrospectively. There is no impact of the amendment on the financial statements.

B. Standards issued but not yet effective

Pursuant to the amendment to Ind AS 1 – Presentation of Financial Statements, where an entity breaches a loan covenant on or before the reporting date and the liability becomes payable on demand, it must be classified as current, even if the lender subsequently agrees not to demand repayment. It is classified as current because, at the reporting date, the entity does not have the right to defer settlement for at least 12 months. However, if the lender has already provided—by the reporting date—a grace period extending at least 12 months beyond that date, during which the breach can be rectified and repayment cannot be demanded, the liability is classified as non-current.

This amendment is to be applied retrospectively for annual reporting periods beginning on or after 1 April 2026, in accordance with Ind AS 8, Accounting Policies, Changes in Accounting Estimates and Errors. The Company does not expect a significant impact of this amendment on the Standalone Financial Statements.

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

5(i)(a) Property, plant and equipment

Particulars	(Amount in ₹ lacs)									
	Freehold land	Buildings	Leasehold improvements	Plant & machinery	Medical equipment	Furniture & fittings	Computers	Office equipment	Vehicles	Total
Gross carrying amount										
As at April 01, 2024 (refer note 24)	53,727.54	49,055.59	509.63	8,799.07	53,053.44	1,574.78	2,173.27	802.68	158.12	169,854.13
Additions	3.47	1,319.92	71.56	1,525.98	8,029.50	239.56	430.43	128.92	138.29	11,887.63
Disposals	(7,691.59)	(1.78)	-	(130.36)	(900.02)	(152.87)	(78.43)	(49.97)	(13.98)	(9,019.00)
As at March 31, 2025	46,039.42	50,373.73	581.19	10,194.70	60,182.92	1,661.47	2,525.26	881.62	282.43	172,722.76
Additions	10,824.32	12,632.34	107.82	4,086.52	15,712.18	1,526.46	492.45	381.65	144.62	45,908.36
Disposals	-	(9.48)	-	(71.55)	(1,032.73)	(15.02)	(33.64)	(23.18)	-	(1,185.60)
As at March 31, 2026	56,863.74	62,996.59	689.01	14,209.67	74,862.37	3,172.91	2,984.07	1,240.09	427.05	217,445.52
Accumulated depreciation										
As at April 01, 2024 (refer note 24)	-	16,227.15	416.04	3,658.20	19,176.82	844.05	1,269.59	569.54	91.10	42,252.51
Charge for the year	-	1,877.51	127.27	598.53	3,956.26	144.20	535.74	81.89	26.11	7,347.51
Disposals	-	(1.39)	-	(89.91)	(897.51)	(146.44)	(78.43)	(49.97)	(3.38)	(1,267.04)
Impairment reversal [(Refer note 22)]	-	-	-	(36.41)	(248.88)	(0.86)	-	-	-	(286.15)
As at March 31, 2025	-	18,103.28	543.31	4,130.41	21,986.69	840.95	1,726.91	601.46	113.82	48,046.83
Charge for the year	-	1,758.16	118.25	818.79	4,833.92	243.39	585.93	128.29	48.91	8,535.64
Disposals	-	(6.78)	-	(71.55)	(685.01)	(14.01)	(33.33)	(22.51)	-	(833.19)
As at March 31, 2026	-	19,854.66	661.56	4,877.64	26,135.60	1,070.33	2,279.51	707.24	162.73	55,749.28
Carrying value										
As at March 31, 2025	46,039.42	32,270.45	37.88	6,064.29	38,196.23	820.52	798.35	280.16	168.61	124,675.93
As at March 31, 2026	56,863.74	43,141.93	27.45	9,332.03	48,726.77	2,102.58	704.56	532.85	264.32	161,696.23

Notes:

- Refer note 9 for details in respect of assets pledged with banks against the loans taken by the Company.
- The Company has not revalued its property, plant and equipment during the current and previous year.
- The Company do not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- Movable property, plant and equipment are hypothecated against loan taken by the Company refer note 5 (xvii),5 (xx) and 8.
- Details of Title deeds of Immovable Property not held in the name of the Company.

Relevant line item in the Balance sheet	Description of item of property	Gross carrying value (Amount in ₹ lacs)	Title deeds held in the name of	Whether title deed holder is a promoter, director or relative of promoter/director or employee of promoter/director	Property held since which date	Reason for not being held in the name of the company
Property, plant and equipment	Land in Faridabad	6,151.08	Escorts Hospital and Research Center Limited	Not applicable	Since 2014	The title deeds are in the name of Escorts Hospital and Research Centre Limited, erstwhile Company that was merged with the Company subsequent to a scheme of merger sanctioned by the High Court of Punjab and Haryana, which came into effect on January 17, 2014.
Property, plant and equipment	Land in Mulund, Mumbai	30,190.00	Kanishka Healthcare Limited	Not applicable	Since 2014	The title deeds are in the name of Kanishka Healthcare Limited, erstwhile Company that was merged with the Company subsequent to a scheme of merger sanctioned by the High Court of Punjab and Haryana, which came into effect on January 17, 2014.
Property, plant and equipment	Land in Kolkata	1,230.17	Fortis Hospitals Limited	Not applicable	Since 2023	The title deeds are in the name of Fortis Hospitals Limited (FHsL). Pursuant to the composite scheme of arrangement sanctioned by the NCLT of Chandigarh and Delhi Bench, some undertakings of FHsL were merged with the Company, with an appointed date of April 01, 2023.

Note:

- In case of immovable property situated at Anandpur- Kolkata location, the title deed is under dispute. The Company has been legally advised that it has the title deed in its name for the aforesaid immovable property and that it will be able to defend any counter claims against it.

5(i)(b) Capital work-in-progress

(Amount in ₹ lacs)

Particulars	As at	
	March 31, 2026	March 31, 2025
Opening Balance (refer note 24)	26,771.20	12,887.15
Additions *	31,197.62	25,771.68
Transfer to property, plant and equipment	(45,908.36)	(11,887.63)
Closing balance	12,060.46	26,771.20

* The Company accounts for all capitalization of property, plant and equipment through capital work in progress and therefore the movement in capital work in progress is the difference between closing and opening balance of capital work in progress as adjusted for additions to property, plant and equipment.

Aging schedule:

As at March 31, 2026

CWIP	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	4,695.66	356.09	24.31	6,984.40	12,060.46
Projects temporarily suspended	-	-	-	-	-
Total	4,695.66	356.09	24.31	6,984.40	12,060.46

Details of Projects whose completion is overdue or has exceeded its cost compared to its original plan

Capital work-in-progress	To be completed in				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Amritsar hospital project	541.35	-	206.39	-	747.74
Bannerghatta Road hospital project	6,847.80	-	-	-	6,847.80
Noida expansion project	1,825.85	-	-	-	1,825.85
Civil work at FHKI Anandpur	788.93	-	-	-	788.93
Civil work for project at Mulund	157.10	-	-	-	157.10

As at March 31, 2025

CWIP	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	15,728.00	3,586.37	479.91	6,976.92	26,771.20
Projects temporarily suspended	-	-	-	-	-
Total	15,728.00	3,586.37	479.91	6,976.92	26,771.20

Details of Projects whose completion is overdue or has exceeded its cost compared to its original plan

Capital work-in-progress	To be completed in				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Amritsar hospital project	-	-	122.06	-	122.06
Bannerghatta Road hospital project	6,847.80	-	-	-	6,847.80
Civil work at FHKI Anandpur	228.92	-	-	-	228.92

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

5(ii) Goodwill

(Amount in ₹ lacs)

Particulars	March 31, 2026			March 31, 2025				
	As at April 01, 2025 (Restated)	Addition	Impairment	As at March 31, 2026	As at April 01, 2024 (refer note 24)	Addition	Impairment	As at March 31, 2025
Carrying Amount								
Hospital Business								
Fortis Hospital, Banergatta Road	4.98	-	-	4.98	4.98	-	-	4.98
Fortis Hospital, Kalyan	1,640.63	-	-	1,640.63	1,640.63	-	-	1,640.63
Fortis Hospital, Mulund	13,402.39	-	-	13,402.39	13,402.39	-	-	13,402.39
Fortis Heart and Kidney Institute, Kolkata	1,984.82	-	-	1,984.82	1,984.82	-	-	1,984.82
Fortis Hospital Anandapur, Kolkata	6,503.88	-	-	6,503.88	6,503.88	-	-	6,503.88
Fortis Hospital, Noida	482.00	-	-	482.00	482.00	-	-	482.00
Fortis Escorts Hospital, Amritsar	295.15	-	-	295.15	295.15	-	-	295.15
Total	24,313.85	-	-	24,313.85	24,313.85	-	-	24,313.85

At cash generating unit (CGUs) level, the goodwill is tested for impairment annually at the year-end or more frequently if there are indications that goodwill might be impaired.

The Company made an assessment of recoverable amount of the CGUs based on value-in-use calculations which uses cash flow projections based on financial budgets approved by management. Cash flow projections were developed covering a seven-year period as at March 31, 2026 and March 31, 2025 which reflects a more appropriate indication/trend of future track of business of the Company. Cash flows beyond the seven-year period were extrapolated using estimate rates stated below.

The key assumptions for the value-in-use calculations are those regarding the discount rates, growth rates and expected changes to direct costs during the year. Management estimates discount rates using post-tax rates that reflect current market assessments of the time value of money and the risks specific to the CGUs. The growth rates are based on industry growth forecasts. Changes in selling prices and direct costs are based on past practices and expectations of future changes in the market.

Key assumptions used for value in use calculations are as follows:

Particulars	As at March 31, 2026	As at March 31, 2025
Compound average net sales growth rate for seven-year period (p.a.)	2%-11%	4%-10%
Growth rate used for extrapolation of cash flow projections beyond seven-year period (refer note below)	4% p.a.	4% p.a.
Discount rate (p.a.) (Post tax rate)	11.82% p.a.	11.31% p.a.
Discount rate (p.a.) (Pre tax rate)	15.79% p.a.	15.11% p.a.

Management believes that any reasonable possible change in any of these assumptions would not cause the carrying amount to exceed its recoverable amount.

Discount rates - Management estimates discount rates using post-tax rates that reflect current market assessments of the risks specific to the CGU, taking into consideration the time value of money and individual risks of the underlying assets that have not been incorporated in the cash flow estimates. The discount rate calculation is based on the specific circumstances of the Company and its operating segments and is derived from its weighted average cost of capital (WACC).

Growth rates - The growth rates are based on industry growth forecasts. Management determines the budgeted growth rates based on past performance and its expectations of market development. The weighted average growth rates used were consistent with industry reports.

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

5(iii)(a) Other intangible assets

Particulars	(Amount in ₹ lacs)		
	License fee	Computer Software	Total
Gross carrying amount			
As at April 01, 2024 (refer note 24)	445.75	2,804.39	3,250.14
Additions	-	297.44	297.44
As at March 31, 2025	445.75	3,101.83	3,547.58
Additions	-	94.92	94.92
Deletions	(0.40)	(2.64)	(3.05)
As at March 31, 2026	445.35	3,194.11	3,639.45
Accumulated amortisation			
As at April 01, 2024 (refer note 24)	376.40	2,481.97	2,858.37
Charge for the year	24.64	111.32	135.96
As at March 31, 2025	401.04	2,593.29	2,994.33
Charge for the year	18.90	135.36	154.26
Deletions	(0.40)	(2.64)	(3.04)
As at March 31, 2026	419.55	2,726.01	3,145.55
Carrying value			
As at March 31, 2025	44.71	508.54	553.25
As at March 31, 2026	25.80	468.10	493.90

(a) The Company has not revalued its intangible assets during the current and previous year.

5(iii)(b) Intangible assets under development

Particulars	(Amount in ₹ lacs)	
	As at March 31, 2026	As at March 31, 2025 (Restated)
Opening Balance	158.13	42.00
Additions *	78.92	413.57
Transfer to intangible assets	(94.92)	(297.44)
Closing balance	142.13	158.13

* The Company accounts for all capitalisation of intangible assets through intangible assets under development and therefore the movement in intangible assets under development is the difference between closing and opening balance of intangible assets under development as adjusted for additions to intangible assets.

Aging schedule:

As at March 31, 2026

Intangible assets under development	Amount in intangible assets under development for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	63.56	69.01	9.56	-	142.13
Projects temporarily suspended	-	-	-	-	-
Total	63.56	69.01	9.56	-	142.13

As at March 31, 2025 (Restated)

Intangible assets under development	Amount in intangible assets under development for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	136.44	21.70	-	-	158.13
Projects temporarily suspended	-	-	-	-	-
Total	136.44	21.70	-	-	158.13

There is no project whose completion is overdue or has exceeded its cost compared to its original plan as at March 31, 2026 and March 31, 2025

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Particulars	As at March 31, 2026 (Amount in ₹ lacs)	As at March 31, 2025 (Amount in ₹ lacs) (Restated)
5(iv) Investments		
Non-Current		
Unquoted investment		
(a) Investment in redeemable preference shares at amortised cost		
i) Fortis Health Management Limited (Associate)*		
29,000 (29,000 as at March 31, 2025) Preference shares of ₹ 10,000 each (including premium of ₹ 9,990 per share)	14,317.47	12,846.49
62,803 (62,803 as at March 31, 2025) Preference shares of ₹ 12,000 each (including premium of ₹ 11,990 per share)	32,547.74	29,209.31
Total investment in preference shares	46,865.21	42,055.80
(b) Investment in equity instruments measured at cost		
i) Fortis Health Management Limited (Associate)*	1,156.88	1,156.88
1,200,000 (1,200,000 as at March 31, 2025) equity shares of ₹10 each		
ii) Escorts Heart and Super Speciality Hospital Limited (Associate)*	1,298.94	1,298.94
12,990,000 (12,990,000 as at March 31, 2025) equity shares of ₹ 10 each [(Of the above, 6 shares (6 shares as at March 31, 2025) are held by nominee share holders)]		
iii) TMI Healthcare Private Limited (Wholly owned subsidiary)	27,225.75	-
23,02,419 (Nil as at March 31, 2025) equity shares of ₹10 each [(Of the above, 6 shares (Nil shares as at March 31, 2025) are held by nominee share holders)]		
Investment in equity shares	29,681.57	2,455.82
(c) Investment in debentures at amortised cost		
i) Hospitalia Eastern Private Limited (Fellow subsidiary)	7,800.00	7,800.00
780,000 (780,000 as at March 31, 2025) unsecured 9% optionally convertible debentures of ₹ 1,000 each		
	7,800.00	7,800.00
Less: Impairment in value of Investment	(7,800.00)	(7,800.00)
Investment in debentures	-	-
(d) Investment in 0.01% Optionally convertible redeemable preference shares - at cost		
i) Fortis Health Management Limited (Associate)*	100,706.71	100,706.71
1,007,067,149 (1,007,067,149 as at March 31, 2025) Optionally convertible redeemable preference shares of ₹ 10 each		
Investment in Optionally convertible redeemable preference shares	100,706.71	100,706.71
(e) Unquoted investment		
Investments in equity instruments at cost		
i) Renew Wind Energy AP Private Limited	12.30	12.30
74,500 (74,500 as at March 31, 2025) equity shares of ₹ 10 each**		
	12.30	12.30
Aggregate carrying value of unquoted investments (a-e)	177,265.79	145,230.63
Aggregate gross value of unquoted investments	185,065.79	153,030.63
Aggregate amount of impairment in value of investments	7,800.00	7,800.00

* The Company uses judgement while classifying its investment. The Company while making classification assessment of the investment in equity shares of respective companies has referred to the criteria of significant influence given in Ind AS 28 "Investment in associates and joint venture" and primarily concluded that Company meets the criteria of significant influence over these investees and therefore, has classified these investments as investment in Associate. In terms of Ind AS 27 "Separate Financial Statements" the Company has measured this Investment in Associate at cost.

**The Company has entered into an energy purchase agreement with Renew Wind Energy AP Private Limited (the "issuer"). As per terms of the agreement, the Company needs to keep the money invested in the equity shares of issuer till the period electricity would be purchased from the issuer. The shares would be redeemed at the time of termination of the contract upon mutual consent by the parties. The Company can't sell these shares in active market. Given these facts, the Company has accounted these instruments at cost.

5(v) Trade receivables

Current

(unsecured, unless stated otherwise)

(a) Considered good		
From Others		
-Billed	29,790.53	21,713.29
-Unbilled	3,363.07	2,245.19
From Related Parties	3,063.77	4,555.72
Less: Loss allowance	(1,992.43)	(1,934.82)
	34,224.94	26,579.38

In accordance with Ind AS 109, the Company applies Expected Credit Loss (ECL) model for measurement and recognition of impairment loss towards expected risk of delays and default in collection.

(a) Trade receivables- IPD and OPD income (Hospital operations)

Trade receivables are unsecured and are derived from revenue earned from providing healthcare and other ancillary services. No interest is charged on the outstanding balance, regardless of the age of the balance. In accordance with Ind AS 109, the Company applies Expected Credit Loss (ECL) model for measurement and recognition of impairment loss towards expected risk of delays and default in collection. The Company has used a practical expedient by computing the expected credit loss allowance based on a provision matrix. Management makes specific provision in cases where there are known specific risks of customer default in making the payments. The provision matrix takes into account historical credit loss experience and adjusted for forward- looking information. The expected credit loss allowance is based on the ageing of the days the receivables are due and the rates as given in the provision matrix. The provision matrix at the end of the reporting period is as follows:

Payor Ageing	Expected credit allowance %	
	As at March 31, 2026	As at March 31, 2025
0 - 1 year	0% - 22%	0% - 26%
1 - 2 year	7% - 41%	8% - 42%
2 - 3 year	22% - 78%	25% - 73%
More than 3 years	100%	100%

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Particulars	As at March 31, 2026 (Amount in ₹ lacs)	As at March 31, 2025 (Amount in ₹ lacs) (Restated)
-------------	---	---

Note 5(v) Contd.

The movement in Expected Credit Loss during the year is as follows :

Particulars	As at March 31, 2026 (Amount in ₹ lacs)	As at March 31, 2025 (Amount in ₹ lacs) (Restated)
Balance at the beginning of the year	1,934.82	3,146.91
Creation of the allowance for expected credit loss	1,434.89	1,287.41
Utilisation of the allowance for expected credit loss (written off)	(1,377.28)	(2,499.50)
Balance at the end of the year	1,992.43	1,934.82

The Company does not have any significant concentration of exposures to specific category of customer.

The Company does not required collateral in respect of trade receivables. The company does not have trade receivables for which no loss allowance is recognised because of collateral.

(b) Trade receivables- Income from hospital and medical services & income from rent:

As per terms of Hospital and Medical Services Agreements(HMSA), the average credit period allowed is 05-11 days.For the outlet vendors with whom rental arrangements have been entered into by the Company, average credit period is upto 30 days.

Trade receivables are unsecured and are derived from revenue earned from providing clinical establishment and other ancillary services. The risk of non-payment from the customer is considered low, as majority of the total balances are due from related parties for which the default risk is considered low.

The Company uses its judgements in making certain assumptions and selecting inputs to determine impairment of these trade receivables, based on the Company's historical experience towards potential billing adjustments, delays and defaults at the end of each reporting period. The provision matrix used to compute the expected credit loss allowance for trade receivables (other than due from related party) are as follows:

Ageing bucket	Expected credit allowance%	
	March 31, 2026	March 31, 2025
0 - 6 months	-	-
More than 6 months	100%	100%

The hospital operating company (related party) has confirmed that it has the ability and intention to settle the outstanding dues payable to the Company in due course. Hence, the Company believes that no adjustment is required to be carried out in its financial statements as at and for the year ended March 31, 2026 & March 31, 2025 with respect to the outstanding receivables, other than those already made.

(c) Ageing schedule of trade receivables

As at March 31, 2026

	Particulars	Not due	Outstanding for following periods from due date of payment					Total
			Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	
(i)	Undisputed Trade receivables – considered good	23,779.13	6,943.36	1,188.22	574.24	120.28	249.07	32,854.30
(ii)	Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
(iii)	Undisputed Trade Receivables – credit impaired	-	-	-	-	-	-	-
(iv)	Disputed Trade Receivables – considered good	-	-	-	-	-	-	-
(v)	Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
(vi)	Disputed Trade Receivables – credit impaired	-	-	-	-	-	-	-
		23,779.13	6,943.36	1,188.22	574.24	120.28	249.07	32,854.30
	Less: Allowance for doubtful trade receivables - Billed							(1,992.43)
								30,861.87
	Trade receivables - unbilled							3,363.07
								34,224.94

As at March 31, 2025

	Particulars	Not due	Outstanding for following periods from due date of payment					Total
			Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	
(i)	Undisputed Trade receivables – considered good	17,643.70	4,863.88	2,086.02	412.41	38.02	1,224.98	26,269.01
(ii)	Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
(iii)	Undisputed Trade Receivables – credit impaired	-	-	-	-	-	-	-
(iv)	Disputed Trade Receivables – considered good	-	-	-	-	-	-	-
(v)	Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
(vi)	Disputed Trade Receivables – credit impaired	-	-	-	-	-	-	-
		17,643.70	4,863.88	2,086.02	412.41	38.02	1,224.98	26,269.01
	Less: Allowance for doubtful trade receivables - Billed							(1,934.82)
								24,334.19
	Trade receivables - unbilled							2,245.19
								26,579.38

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Particulars	As at March 31, 2026 (Amount in ₹ lacs)	As at March 31, 2025 (Amount in ₹ lacs) (Restated)
5(vi) Loans		
<u>Non-current - at amortised cost</u>		
Considered good		
(a) Loans to related party (refer note 17(i))	-	120.00
(b) Loan to bodies corporate and others	294.66	294.66
Loans to subsidiaries [refer 17(i)]	294.66	414.66
	(294.66)	(294.66)
	<u>-</u>	<u>120.00</u>
The Company has not granted any loans or advances in the nature of loans to promoters, directors, KMPs and the related parties (as defined under Companies Act, 2013) either severally or jointly with any other person,		
(a) repayable on demand; or		
(b) without specifying any terms or period of repayment		
Break-up of security details		
Loans considered good - Secured	-	-
Loans considered good - Unsecured	-	120.00
Loans considered doubtful - Unsecured	-	-
Total Loans	<u>-</u>	<u>120.00</u>
5(vii) Other financial assets (unsecured)		
<u>Non current</u>		
Considered good		
(a) Deposits with banks*	5.73	4.10
(b) Security deposits	3,970.78	1,011.22
(c) Interest accrued and due on optionally convertible debentures and inter company loans	-	74.76
	<u>3,976.51</u>	<u>1,090.08</u>
Credit impaired		
(a) Interest accrued and due on optionally convertible debentures	5,103.11	5,103.11
	<u>5,103.11</u>	<u>5,103.11</u>
Less: Loss allowance	(5,103.11)	(5,103.11)
	<u>-</u>	<u>-</u>
	<u>3,976.51</u>	<u>1,090.08</u>
*Fixed deposits are pledged with statutory authorities and are restricted from being exchanged for more than 12 months from the balance sheet date.		
<u>Current</u>		
Considered good		
(a) Deposit accounts with banks	77.42	22.11
(b) Interest accrued but not due on bank deposits	7.22	4.15
(c) Derivative forward contract	0.27	-
(d) Others	100.78	44.53
(e) Government grant receivable	80.69	80.69
(f) Amount receivable from related party (Refer Note 6 and 24)*	-	35,466.42
(g) Security deposits	164.15	55.68
(h) Other amount receivable from related party (Refer Note 6 and 24)**	2,563.83	-
	<u>2,994.36</u>	<u>35,673.58</u>
Credit impaired		
(a) Recoverable from other than related parties	31.94	9.59
(b) Others	584.25	564.82
	<u>616.19</u>	<u>574.41</u>
Less: Loss allowance	(616.19)	(574.41)
	<u>-</u>	<u>-</u>
	<u>2,994.36</u>	<u>35,673.58</u>

* Includes intra company receivables transferred from FHsL pursuant to composite scheme of arrangement (refer note 24).

** Includes amount receivable from FHsL for collection from customer made on the behalf of the Company.

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Particulars	As at March 31, 2026 (Amount in ₹ lacs)	As at March 31, 2025 (Amount in ₹ lacs) (Restated)
5(viii) Deferred tax balances		
Deferred tax assets	10,163.37	2,315.89
Deferred tax liabilities	(26,210.09)	(16,993.62)
	(16,046.72)	(14,677.73)

The following is the analysis of the movement in deferred tax assets/(liabilities) presented in financial statements:

(Amount in ₹ lacs)				
	As at April 01, 2025 (Restated)	(Charge)/ Credit to Profit or loss	(Charge)/ Credit to Other comprehensive income	As at March 31, 2026
Deferred tax liabilities				
(a) Property, plant and equipment	(5,622.69)	(1,061.07)	-	(6,683.76)
(b) Preference shares	(4,521.58)	(687.75)	-	(5,209.33)
(c) Interest on non convertible debentures	(471.02)	275.74	-	(195.28)
(d) Right-of-use assets	(283.55)	(7,736.92)	-	(8,020.47)
(e) Intangible Asset	(6,094.78)	(6.47)	-	(6,101.25)
	(16,993.62)	(9,216.47)	-	(26,210.09)
Deferred tax assets				
(a) Allowance for expected credit loss	486.95	14.51	-	501.46
(b) Defined benefit obligation	1,056.60	345.10	0.92	1,402.62
(c) Lease liability	361.12	7,659.11	-	8,020.23
(d) Provision for credit impaired advances	232.11	(61.51)	-	170.60
(e) Disallownce under 43(b)	179.11	(110.65)	-	68.46
	2,315.89	7,846.56	0.92	10,163.37
Deferred tax liabilities (net)	(14,677.73)	(1,369.91)	0.92	(16,046.72)

(Amount in ₹ lacs)				
	As at April 01, 2024 (refer note 24)	(Charge)/ Credit to Profit or loss	(Charge)/ Credit to Other comprehensive income	As at March 31, 2025 (Restated)
Deferred tax liabilities				
(a) Property, plant and equipment	(4,905.90)	(716.79)	-	(5,622.69)
(b) Preference shares	(4,459.29)	(62.29)	-	(4,521.58)
(c) Interest on non convertible debentures	(664.57)	193.55	-	(471.02)
(d) Right-of-use assets	(359.50)	75.95	-	(283.55)
(e) Intangible Asset	(6,075.98)	(18.80)	-	(6,094.78)
	(16,465.24)	(528.38)	-	(16,993.62)
Deferred tax assets				
(a) Allowance for expected credit loss	792.00	(305.05)	-	486.95
(b) Defined benefit obligation	876.34	113.34	66.92	1,056.60
(c) Carry forward business losses and unabsorbed depreciation	2,496.57	(2,496.57)	-	-
(d) Lease liability	411.91	(50.79)	-	361.12
(e) Provision for credit impaired advances	222.26	9.85	-	232.11
(f) Disallownce under 43(b)	84.59	94.52	-	179.11
	4,883.67	(2,634.71)	66.92	2,315.89
Deferred tax liabilities (net)	(11,581.57)	(3,163.09)	66.92	(14,677.73)

5(ix) Non-current tax assets (net)

Current tax assets	27,440.34	26,330.31
Advance income tax (net of provision for taxation of Rupees 14,584.27 lacs Previous year Rupees 5,672.90 lacs)	27,440.34	26,330.31
	27,440.34	26,330.31

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Particulars	As at March 31, 2026 (Amount in ₹ lacs)	As at March 31, 2025 (Amount in ₹ lacs) (Restated)
5(x) Other assets (unsecured)		
Non-current		
Considered good		
(a) Capital advances	405.54	291.16
(b) Technology renewal fund	581.25	506.25
(c) Deposit paid under protest- Service tax matters	254.92	157.65
(d) Prepaid expenses	125.95	201.58
	1,367.66	1,156.64
Considered Doubtful		
(a) Capital advances	12.77	9.53
Less: Loss allowance	(12.77)	(9.53)
	-	-
	1,367.66	1,156.64
Current		
Considered good		
(a) Balances with government authorities - Goods and service tax recoverable and provident fund	599.75	613.00
(b) Advance to vendors	216.79	89.21
(c) Prepaid expenses	641.52	732.66
	1,458.06	1,434.87
Considered doubtful		
(a) Balances with service tax and other authorities	38.99	38.99
(b) Advance to vendors	-	7.04
(c) Others	8.81	8.81
	47.80	54.84
Less: Loss allowance	(47.80)	(54.84)
	-	-
5(xi) Inventories		
Valued at lower of cost and net realisable value		
Medical consumables, drugs and others	2,918.40	2,241.56
	2,918.40	2,241.56
5(xii)(a) Cash and cash equivalents		
For the purposes of the statement of cash flows, cash and cash equivalents include cash on hand and in banks. Cash and cash equivalents at the end of the reporting period as shown in the statement of cash flows can be reconciled to the related items in the balance sheet as follows:		
(a) Balances with banks		
-in current accounts	857.38	27.48
(b) Cash on hand	209.17	166.58
Cash and cash equivalents as per balance sheet	1,066.55	194.06
Bank overdrafts (refer note 5(xv))	(751.23)	(746.42)
Cash and cash equivalents as per statement of cash flows	315.32	(552.36)
5(xii)(b) Balances with banks		
-Deposits with original maturity of more than 3 months but less than 12 months*	46.01	86.00
	46.01	86.00

*Includes deposits held with government authority amounting to ₹ 39.52 lacs (previous year: ₹ 39.36 lacs)

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Particulars	As at March 31, 2026 (Amount in ₹ lacs)	As at March 31, 2025 (Amount in ₹ lacs) (Restated)
	5(xiii) Share capital	
Authorised share capital:*		
87,948,898 (87,948,898 as at March 31, 2025) equity shares of ₹100 each	87,948.90	87,948.90
10,476,793 (10,476,793 as at March 31, 2025) preference shares of ₹10 each	1,047.68	1,047.68
Total authorised share capital	88,996.58	88,996.58
*Authorised share capital stands increased pursuant to composite scheme of arrangement (refer note 24)		
Issued, subscribed and fully paid up shares		
Equity Share Capital		
87,948,898 (87,948,898 as at March 31, 2025) equity shares of ₹100 each	87,948.90	87,948.90
Instruments entirely equity in nature		
10,476,793 (10,476,793 as at March 31, 2025) 0.01% Non-cumulative compulsory convertible preference shares ('CCPS') of ₹10 each	1,047.68	1,047.68
Total issued, subscribed and fully paid up share capital	88,996.58	88,996.58

Notes :

(a) Reconciliation of the shares outstanding at the beginning and at the end of the reporting period

Equity Shares

Particulars	March 31, 2026		March 31, 2025 (Restated)	
	Number	Amount in ₹ lacs	Number	Amount in ₹ lacs
At the beginning of the year (refer note 24)	87,948,898	87,948.90	87,948,898	87,948.90
Add: Shares issued during the year	-	-	-	-
Outstanding at the end of the year	87,948,898	87,948.90	87,948,898	87,948.90

Non-cumulative compulsory convertible preference shares

Particulars	March 31, 2026		March 31, 2025 (Restated)	
	Number	Amount in ₹ lacs	Number	Amount in ₹ lacs
At the beginning of the year (refer note 24)	10,476,793.00	1,047.68	10,476,793.00	1,047.68
Add: Shares issued during the year	-	-	-	-
Outstanding at the end of the year	10,476,793	1,047.68	10,476,793	1,047.68

(b) Terms/ rights attached to equity shares

Equity Shares

The Company has only one class of equity shares having par value of Rupees 100 per share. Each holder of equity shares is entitled to one vote per share. Where dividend is proposed by the Board of Directors, it is subject to the approval of the shareholders in the ensuing Annual General Meeting. In the current and previous year, there has been no dividend proposed by the Board of Directors. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the company after distribution of all preferential amount. The distribution will be in proportion to the number of equity shares held by the shareholders.

0.01% Non-cumulative compulsory convertible preference shares

The preference shares are compulsorily convertible on expiry of 10 years from the date of the allotment, or at the option of the investor, anytime after completion of 3 years. The holder of these preference shares will be entitled for 1 equity share for each preference share held by them. Holder of CCPS shall have voting rights relating to liquidation or a resolution or any other matter which directly affects or varies the right of the holders. 0.01% CCPS are compound instruments as it also contain liability towards payment of 0.01% dividend at the end of the period of 10 years or at the time of conversion. Such liability component is insignificant to the total instrument and therefore, not segregated from the instrument value.

(c) Shares held by the holding/ ultimate holding company and/ or their subsidiaries

Equity shares

Name of Shareholder	As at March 31, 2026		As at March 31, 2025 (Restated)	
	No. of Shares held	Amount in ₹ lacs	No. of Shares held	Amount in ₹ lacs
Fortis Healthcare Limited	80,613,072	80,613.07	80,613,072	80,613.07
Fortis Health Management Limited, fellow subsidiary*	7,335,826	7,335.83	7,335,826	7,335.83

*including 6 equity shares held by its nominees.

0.01% Non-cumulative compulsory convertible preference shares

Name of Shareholder	As at March 31, 2026		As at March 31, 2025 (Restated)	
	No. of Shares held	Amount in ₹ lacs	No. of Shares held	Amount in ₹ lacs
Escorts Heart Institute and Research Centre Limited	10,476,793	1,047.68	10,476,793	1,047.68

(d) Details of shareholders holding more than 5% shares in the Company

Equity Shares

Name of Shareholder	As at March 31, 2026		As at March 31, 2025 (Restated)	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding
Fortis Healthcare Limited	80,613,072	91.66%	80,613,072	91.66%
Fortis Health Management Limited, fellow subsidiary*	7,335,826	8.34%	7,335,826	8.34%

*including 6 equity shares held by its nominees.

0.01% Non-cumulative compulsory convertible preference shares

Name of Shareholder	As at March 31, 2026		As at March 31, 2025 (Restated)	
	No. of Shares held	Amount in ₹ lacs	No. of Shares held	Amount in ₹ lacs
Escorts Heart Institute and Research Centre Limited	10,476,793	100.00%	10,476,793	100.00%

As per records of the Company, including its register of share holders/members and other declarations received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownership of shares.

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(e) **Aggregate number of equity shares issued for consideration other than cash during the period of five years immediately preceding the reporting date:**

During the year ended March 31, 2024, pursuant to the composite scheme of arrangement, the Company had issued 53,985,768 Equity Shares to the Fortis Healthcare Limited and 10,476,793 0.01% Non-cumulative compulsory convertible preference shares to the Escorts Heart Institute and Research Centre Limited for consideration other than cash. Further, there was no bonus and buyback (refer note 24).

(f) **Details of equity shares held by promoters**

As at March 31, 2026

Equity Shares

Promoter Name	No. of shares at the beginning of the year	Change during the year	No. of shares at the end of the year	% of Total Shares	% change during the year
Fortis Healthcare Limited	80,613,072	-	80,613,072	91.66%	0.00%
Fortis Health Management Limited, fellow subsidiary*	7,335,826	-	7,335,826	8.34%	0.00%

*including 6 equity shares held by it's nominees.

As at March 31, 2025

Equity Shares

Promoter Name	No. of shares at the beginning of the year (refer note 24)	Change during the year	No. of shares at the end of the year	% of Total Shares	% change during the year
Fortis Healthcare Limited	80,613,072	-	80,613,072	91.66%	0.00%
Fortis Health Management Limited, fellow subsidiary*	7,335,826	-	7,335,826	8.34%	0.00%

*including 6 equity shares held by it's nominees.

(g) **Shares reserved for issue under contracts**

Name of Shareholder	As at March 31, 2026		As at March 31, 2025	
	No. of Shares held	Amount in ₹ lacs	No. of Shares held	Amount in ₹ lacs
For compulsory convertible non-cumulative preference shares, 1,04,76,793 equity shares of Rupees 10 each	10,476,793	1,047.68	10,476,793	1,047.68

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Note 5(xiv) Changes in liabilities arising from financing activities

Particulars	Non-current borrowings (including current maturity)	Current borrowings	Interest accrued	Lease liabilities
As at April 01, 2024 (refer note 24)	71,296.07	62,633.93	50,155.29	1,768.16
Proceeds from long-term borrowings	77.08	-	-	-
Repayment of long-term borrowings	(3,886.33)	(19,873.93)	-	-
Finance costs*	-	-	15,307.56	146.48
Finance costs paid	-	-	(13,489.41)	(146.48)
Payment of lease liabilities	-	-	-	(333.32)
As at March 31, 2025	67,486.82	42,760.00	51,973.44	1,434.84
Proceeds from long-term borrowings	19,659.49	-	-	-
Repayment of borrowings	(12,289.82)	-	-	-
Finance costs*	-	-	13,819.30	1,744.55
Finance costs paid	-	-	(19,717.26)	(1,744.55)
Payment of lease liabilities	-	-	-	(443.27)
Addition of lease contracts	-	-	-	33,841.98
As at March 31, 2026	74,856.49	42,760.00	46,075.48	34,833.55

*Excludes finance cost on defined benefit plan and other long term benefits

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Particulars	As at March 31, 2026 (Amount in ₹ lacs)	As at March 31, 2025 (Amount in ₹ lacs) (Restated)
	5(xviii) Trade payables	
(a) Total outstanding dues of micro enterprises and small enterprises (refer note 13)	2,178.39	2,430.37
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	25,069.96	19,122.80
	27,248.35	21,553.17

Of the above trade payables amounts due to related parties are as below:
Trade Payables due to related parties (Refer note 6)

2,399.44	1,394.39
-----------------	-----------------

Particulars	Unbilled	Outstanding for March 31 2026 from due date of payment					
		Not due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	-	1,948.44	209.89	0.23	19.46	0.37	2,178.39
(ii) Others	7,363.88	8,947.23	4,689.76	3,037.87	979.00	52.22	25,069.96
(iii) Disputed dues – MSME	-	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-	-
	7,363.88	10,895.67	4,899.65	3,038.10	998.46	52.59	27,248.35

Particulars	Unbilled	Outstanding for March 31 2025 from due date of payment					
		Not due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	-	2,030.93	371.77	21.55	5.57	0.54	2,430.37
(ii) Others	4,608.65	10,329.99	4,013.73	100.84	21.63	47.96	19,122.80
(iii) Disputed dues – MSME	-	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-	-
	4,608.65	12,360.92	4,385.50	122.39	27.20	48.50	21,553.17

5(xix) Other liabilities

Non-current

(a) Deferred revenue against free of cost assets	7.50	21.42
	7.50	21.42

Current

(a) Contract liability		
- Advance from patients	1,445.10	1,119.13
- Deferred revenue	106.66	112.75
(b) Statutory dues payable	2,642.57	3,102.10
	4,194.33	4,333.98

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Particulars	Year ended March 31, 2026 (Amount in ₹ lacs)	Year ended March 31, 2025 (Amount in ₹ lacs) (Restated)
5(xx) Revenue from operations		
I. Revenue from contracts with customers		
(a) Sale of services		
Healthcare services		
i) Operating income - in patient department	213,111.44	178,373.17
ii) Operating income - out patient department	29,205.84	24,810.75
iii) Laboratory/ clinical services	10.72	9.77
iv) Income from medical services	38.57	180.27
v) Income from hospital and medical services	8,090.47	7,736.26
vi) Income from clinical research	-	13.99
Less: Trade discounts	(11,156.20)	(9,610.67)
	239,300.84	201,513.54
(b) Sale of products - Trading		
i) Out patient pharmacy	8,081.76	6,073.57
Less: Trade discounts	(478.87)	(359.89)
	7,602.89	5,713.68
I. Total revenue from contracts with customers (A+B)	246,903.73	207,227.22
Timing of revenue recognition		
Goods transferred at a point in time	7,602.89	5,713.68
Service transferred at a point in time	27,946.60	23,832.26
Services transferred over time	211,354.24	177,681.28
Total revenue from contracts with customers	246,903.73	207,227.22
Contract balances		
Contract assets (unbilled revenue)	3,363.07	2,245.19
Contract liabilities (advance from patients and deferred revenue)	1,551.76	1,231.88
Out of the above contract balances, the revenue recognised during the current year is the balancing number of opening and closing balances of contract assets and contract liabilities.		
II. Other operating revenues		
i) Income from rent [refer note 7(b)(i)]	512.39	327.95
ii) Income from Academic Services	133.58	214.43
iii) Liabilities no longer required written back	444.04	316.73
iv) Sponsorship income	78.60	-
v) Income from sale of plasma	72.59	-
vi) Miscellaneous income	249.79	212.17
II. Total other operating revenues	1,490.99	1,071.29
Total revenue from operations (I+II)	248,394.72	208,298.51
5(xxi) Other income		
(a) Interest income on		
i) Bank deposits	66.10	338.40
ii) Optionally convertible debentures	64.04	1,246.16
iii) Preference shares	4,809.41	4,315.86
iv) Loan to related party	45.24	1.09
v) Interest on financial assets carried at amortised cost	93.68	13.59
vi) Others	79.53	24.78
	5,158.00	5,939.88
(b) Other non-operating income		
i) Profit on sale of property, plant and equipment (net)	-	3,893.38
ii) Miscellaneous income	10.74	0.31
	10.74	3,893.69
Total other income (a+b)	5,168.74	9,833.58

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Particulars	Year ended March 31, 2026 (Amount in ₹ lacs)	Year ended March 31, 2025 (Amount in ₹ lacs) (Restated)
5(xxii) Changes in inventories of medical consumable and drugs		
(a) Inventory at the beginning of the year (refer note 24)	2,241.56	2,049.03
(b) Inventory at the end of the year	2,918.39	2,241.56
Changes in inventories [(a)-(b)]	(676.83)	(192.53)
5(xxiii) Employee benefits expense		
(a) Salaries, wages and bonus	24,518.05	21,483.38
(b) Gratuity expense (refer note 10)	475.45	340.39
(c) Compensated absences	209.32	170.28
(d) Contribution to provident and other funds	1,308.83	1,097.31
(e) Staff welfare expenses	1,015.62	855.12
	27,527.27	23,946.48
5(xxiv) Finance costs		
(a) Interest expense on		
i) term loans	1,647.22	2,003.50
ii) on defined benefit plan and other long term benefits	297.98	240.18
iii) optionally convertible debentures	-	1,152.70
iv) non-convertible debentures	11,337.85	11,011.27
v) lease liabilities [refer note 7(a)]	1,744.55	146.48
vi) cash credit	143.94	200.92
vii) other borrowings	39.07	139.00
(b) Other borrowing costs	651.27	559.99
	15,861.88	15,454.04
5(xxv) Depreciation and amortisation expense		
(a) Depreciation of property, plant and equipment [refer note 5(i)(a)]	8,535.64	7,347.51
(b) Depreciation of right-of-use assets [refer note 7(a)]	1,933.61	480.82
(c) Amortisation of intangible assets [refer note 5(iii)(a)]	154.26	135.96
	10,623.51	7,964.29
5(xxvi) Other expenses		
(a) Contractual manpower	5,035.83	4,318.86
(b) Power and fuel	4,136.37	3,436.67
(c) Housekeeping expenses including consumables	4,334.40	3,800.94
(d) Patient food and beverages	2,280.36	1,992.04
(e) Pathology laboratory expenses	6,577.47	5,522.17
(f) Radiology expenses	274.97	275.95
(g) Cost of medical services	777.10	908.70
(h) Professional and consultation fees to doctors	62,115.71	51,571.23
(i) Repairs and maintenance		
- Buildings	278.52	246.46
- Plant and machinery	6,198.05	4,966.81
- Others	427.58	382.61
(j) Rent [refer note 7(a)]	2,025.17	1,338.07
(k) Legal and professional fee (refer note below)	1,434.80	824.80
(l) Travel and conveyance	847.92	737.38
(m) Rates and taxes	729.46	605.81
(n) Recruitment and trainings	33.19	27.27
(o) Printing and stationary	731.00	621.21
(p) Communication expenses	422.88	355.73
(q) Directors' sitting fees	0.24	0.71
(r) Insurance	373.47	315.98
(s) Marketing and business promotion	5,402.49	4,210.22
(t) Loss on sale of Property, plant and equipment (net)	10.31	-
(u) Allowance for doubtful receivables	1,434.89	1,287.41
(v) Allowance for doubtful advances	141.19	110.94
(w) Corporate Social Responsibility expenses (refer note 18)	511.37	309.77
(x) Miscellaneous expenses	333.84	205.35
	106,868.58	88,373.07

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Particulars	Year ended March 31, 2026 (Amount in ₹ lacs)	Year ended March 31, 2025 (Amount in ₹ lacs) (Restated)
Notes:		
(i) Auditors' remuneration comprises (inclusive of indirect tax)		
(a) Fees as auditors	157.53	110.33
(b) Out of pocket expenses	15.35	11.03
	172.88	121.36
5(xxvii) Exceptional Items		
(a) One time impact of new labour code (refer note 22)	1,081.63	-
(b) Allowance for investment in 9% optionally convertible debentures of Hospitalia Eastern Private Limited (refer note 22)	-	4,056.95
(c) Reversal of impairment of property, plant & equipment of Faridabad hospital (refer note 22)	-	(286.15)
	1,081.63	3,770.80
5(xxviii) Income-tax		
Current tax		
Current income tax charge for the year	8,911.37	5,351.58
Deferred tax		
Deferred tax charge for the year	1,369.92	3,163.08
	10,281.29	8,514.67
Recognised in Other Comprehensive Income		
Deferred tax credit		
Tax related to items that will not be subsequently reclassified to Statement of Profit and Loss	0.92	66.92
	0.92	66.92
The income tax expense for the year can be reconciled to the accounting profit as follows:		
Profit before tax from continuing operations	40,538.19	35,213.71
Enacted income tax rate in India	25.17%	25.17%
Income tax calculated	10,202.65	8,862.59
Effect of items not deductible in determining taxable profit	145.69	94.81
Effect of change in capital gain tax rate	-	(1,048.61)
Effect of tax on income charged at lower rate	(64.41)	(421.72)
Effect of impairment loss on investment	-	1,021.01
Others	(2.64)	6.59
	10,281.29	8,514.67
5(xxix) Earnings per share (EPS)		
Profit as per Statement of Profit and Loss (Amount in ₹ lacs)	30,256.90	26,699.04
Earning used in calculation of basic EPS and diluted EPS	30,256.90	26,699.04
Weighted average number of equity shares outstanding for calculating basic EPS	98,425,691	98,425,691
Weighted average number of equity shares outstanding for calculating diluted EPS	98,425,691	98,425,691
Basic EPS (in ₹)	30.74	27.13
Diluted EPS (in ₹)	30.74	27.13

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

6. Related Party disclosures

A. Names of related parties and related party relationship

Ultimate holding company	IHH Healthcare Berhad
Intermediate Holding company	Integrated Healthcare Holdings Limited
	Parkway Pantai Limited
	Northern TK Venture Pte Ltd
Holding company	Fortis Healthcare Limited ('FHL')
Wholly owned subsidiary	TMI Healthcare Private Limited ('TMI')
Associates* (parties with whom transactions have taken place)	Fortis Health Management Limited ('FHML')
	Escorts Heart and Super Speciality Hospital Limited ('EHSSHL')
Fellow subsidiaries or Joint Venture (parties with whom transactions have taken place)	Hospitalia Eastern Private Limited ('HEPL')
	Agilus Diagnostics Limited
	Fortis Hospitals Limited ('FHsL')
	Escorts Heart Institute and Research Centre Limited ('EHIRCL')
	Fortis C-Doc Healthcare Limited
	Hiranandani Healthcare Private Limited ('HHPL')
	Stellant Capital Advisory Services Private Limited
	Fortis Hospotel Limited ('FHTL')
	Fortis Healthcare Research Foundation (formerly known as Malar Stars Medicare Limited)
Enterprises owned or significantly controlled / influenced by subsidiary of holding/ultimate holding company/ enterprise having significant influence over ultimate holding company (with whom transactions have been taken place)	Acibadem Teknoloji A.S.
Key management personnel ('KMP') / Director	Mr. Manu Kapila, Director (upto September 13, 2024)
	Ms. Shailaja Chandra - Independent Director (upto June 27, 2025)
	Mr. Akshay Oleti, Whole Time Director (upto September 09, 2025)
	Mr. Anil Vinayak, Director
	Dr. Narayani Shivkumar, Director (w.e.f. June 27, 2025)
	Dr. Bishnu Prasad Panigrahi, Director (w.e.f. September 08, 2025 up to February 16, 2026)
	Mr. Ravi Bhatia, Chief Financial Officer
	Mr. Rajesh Kumar, Company Secretary (w.e.f. March 18, 2024 up to July 09, 2024)
	Ms. Priyanka Negi, Company Secretary (w.e.f. December 10, 2024 up to May 01, 2026)
	Mr. Satyendra Chauhan, Company Secretary (w.e.f. May 18, 2026)
	Dr. Ananth Rao Nanjunda, Whole Time Director (w.e.f. February 12, 2026)
	Mr. Indrajit Banerjee, Independent Director (w.e.f. March 30, 2026)

* Since the Company has more than 20% voting power of the investee companies, these have been classified as associate in accordance with the provisions of Ind AS 28.

B. Transactions taken place during the year are as follows:

Transactions details	(Amount in ₹ lacs)	
	Year ended March 31, 2026	Year ended March 31, 2025 (Restated)
Income from hospital and medical services		
Fortis Hospitals Limited	8,090.47	7,736.26
Agilus Diagnostics Limited	24.43	18.79

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Transactions details	Year ended	Year ended
	March 31, 2026	March 31, 2025 (Restated)
Hiranandani Healthcare Private Limited	1.89	7.61
Fortis Healthcare Limited	0.26	0.47
Interest income		
On inter corporate loan to related parties		
Hospitalia Eastern Private Limited	45.24	1.09
On optionally convertible debentures		
Hospitalia Eastern Private Limited	64.04	70.20
Fortis Health Management Limited	-	1,175.96
On preference shares		
Fortis Health Management Limited	4,809.41	4,315.86
Intangible assets acquired		
Acibadem Teknoloji A.S.	-	348.14
Finance costs		
On optionally convertible debentures		
Escorts Heart and Super Specialty Hospital Limited	-	1,152.70
On non-convertible debentures		
Fortis Healthcare Limited	5,897.60	5,897.60
Fortis Hospotel Limited	5,440.25	5,113.67
Expenses incurred on behalf of the Company by		
Fortis Hospitals Limited	11.83	24.32
Agilus Diagnostic Limited	1.99	0.99
Fortis Health Management Limited	-	0.60
Hiranandani Healthcare Private Limited	59.97	30.64
Fortis Hospotel Limited	2.06	-
Fortis Healthcare Limited	2.92	0.22
Expenses incurred on behalf of		
Fortis Hospitals Limited	518.28	544.02
Fortis Health Management Limited	18.72	19.65
Hiranandani Healthcare Private Limited	-	34.46
Transfer of employee benefit liability to Company from		
Fortis Hospitals Limited	33.10	1.78
Fortis Healthcare limited	0.63	14.66
Fortis Health Management Limited	0.12	-
Hiranandani Healthcare Private Limited	10.30	0.72
Fortis Hospotel Limited	6.37	14.97
Transfer of employee benefit liability by Company to		
Fortis Hospitals Limited	17.45	11.88
Fortis Healthcare limited	26.14	0.73
Escorts Heart Institute & Research Centre Limited	3.53	4.64
Fortis Health Management Limited	2.16	-
Hiranandani Healthcare Private Limited	-	1.34
Fortis Hospotel Limited	7.46	-
Stellant Capital Advisory Services Private Limited	-	15.02

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Transactions details	Year ended	Year ended
	March 31, 2026	March 31, 2025 (Restated)
Advance for research		
Fortis Healthcare Research Foundation	11.34	-
Collection by Company on behalf of		
Fortis Hospitals Limited	77.52	56.58
Fortis Health Management Limited	1.34	1.36
Fortis Healthcare limited	23.81	13.60
Escorts Heart Institute & Research Centre Limited	-	3.48
Fortis Hospotel Limited	343.39	-
Collection by related party on behalf of the Company		
Fortis Hospitals Limited	65.88	61.16
Fortis Healthcare limited	3.95	5.41
Escorts Heart Institute & Research Centre Limited	0.37	1.33
Fortis Health Management Limited	-	1.23
Fortis Hospotel Limited	15.83	-
Professional charges to doctors		
Fortis Hospotel Limited	57.31	56.64
Brand Fees (excluding GST)		
Fortis Healthcare Limited	566.65	-
Hospital service taken for employees from		
Fortis Hospitals Limited	4.41	15.65
Fortis Health Management Limited	-	0.31
Fortis Healthcare Limited	3.99	6.10
Escorts Heart Institute and Research Centre Limited	8.80	4.09
Fortis C-Doc Healthcare Limited	2.21	1.53
Fortis Hospotel Limited	34.59	4.90
Hospital service given to group employees of		
Fortis Hospitals Limited	8.82	15.96
Escorts Heart Institute and Research Centre Limited	10.12	21.00
Fortis Healthcare Limited	27.11	8.43
Fortis Hospotel Limited	18.27	13.02
Hiranandani Healthcare Private Limited	15.78	3.21
Stellant Capital Advisory Services Private Limited	-	2.29
Directors' sitting fee		
Ms. Shailaja Chandra	0.24	0.71
Pathology laboratory expense		
Agilus Diagnostics Limited	6,284.68	5,259.33
Escorts Heart Institute and Research Centre Limited	1.46	-

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Transactions details	Year ended	Year ended
	March 31, 2026	March 31, 2025 (Restated)
Transfer of medical consumables and drugs from		
Fortis Hospitals Limited	126.81	139.09
Fortis Healthcare Limited	-	0.93
Hiranandani Healthcare Private Limited	-	1.12
Rent Expense		
Fortis Hospitals Limited	1.05	-
Transfer of medical consumables to		
Hiranandani Healthcare Private Limited	-	2.72
Fortis Healthcare Limited	4.61	-
Escorts Heart Institute and Research Centre Limited	0.01	0.33
Investment in optionally convertible redeemable preference shares		
Fortis Health Management Limited	-	100,706.71
Provision made against investment in optionally convertible debentures		
Hospitalia Eastern Private Limited	-	4,056.95
Repayment of optionally convertible debentures		
Escorts Heart and Super Speciality Hospital Limited	-	17,775.00
Sale of Property, Plant & Equipment		
Fortis Healthcare Limited	273.00	11,572.00
Income from rent		
TMI Healthcare Private Limited	148.84	-
Interest expense on loan taken from		
Fortis Healthcare Limited	-	125.43
Loan repaid		
Fortis Healthcare Limited	-	2,090.30
Hospitalia Eastern Private Limited	120.00	-
Managerial Remuneration (refer note F below)		
Dr. Narayani Shivkumar		
- Short-term employment benefits	232.44	-
- Post-employment & other long-term benefits	30.43	-

C. Balance outstanding at the year end

(Amount in ₹ lacs)

Particulars	As at	As at
	March 31, 2026	March 31, 2025 (Restated)
Non-current		
Investment in equity shares		
Fortis Health Management Limited	1,156.88	1,156.88
Escorts Heart and Super Speciality Hospital Limited	1,298.94	1,298.94
TMI Healthcare Private Limited	27,225.75	-

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Particulars	As at	As at
	March 31, 2026	March 31, 2025 (Restated)
Investment in preference shares		
Fortis Health Management Limited	46,865.21	42,055.80
Investment in optionally convertible redeemable preference shares		
Fortis Health Management Limited	100,706.71	100,706.71
Investment in optionally convertible debentures (Gross of provision)		
Hospitalia Eastern Private Limited	7,800.00	7,800.00
Provision against investment in optionally convertible debentures		
Hospitalia Eastern Private Limited	7,800.00	7,800.00
Non-Current		
Interest accrued and due on optionally convertible debentures (Gross of provision)		
Hospitalia Eastern Private Limited	5,103.11	5,103.11
Provision against interest accrued and due on optionally convertible debentures		
Hospitalia Eastern Private Limited	5,103.11	5,103.11
Interest accrued and due on loans		
Hospitalia Eastern Private Limited	-	72.39
Advance to vendors		
Fortis Healthcare Research Foundation	11.34	-
Other financial assets		
Amount receivable from		
Fortis Hospitals Limited	2,563.83	35,466.42
TMI Healthcare Private Limited	148.84	-
Trade receivables		
Fortis Hospitals Limited	2,709.32	4,529.53
Fortis Emergency Services Limited	-	4.75
Fortis Healthcare Limited	316.04	2.27
Hiranandani Healthcare Private Limited	35.29	-
Fortis Hospotel Limited	-	19.17
Escorts Heart Institute and Research Centre Limited	0.22	41.96
Stellant Capital Advisory Services Private Limited	2.90	-
Loans		
Non-current		
Inter corporate loan		
Hospitalia Eastern Private Limited	-	120.00
Other assets		
Non-current		
Technology renewal fund		
Fortis Hospitals Limited	581.25	506.25

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Particulars	As at	As at
	March 31, 2026	March 31, 2025 (Restated)
Non-current borrowings		
Non-convertible debentures		
Fortis Hospotel Limited	46,716.77	46,716.77
Current borrowings		
Non-convertible debentures		
Fortis Healthcare Limited	42,760.00	42,760.00
Other financial liabilities		
Interest accrued- Non-current		
Non-convertible debentures		
Fortis Hospotel Limited	36,345.62	31,339.83
Interest accrued- Current		
Compulsorily convertible debentures		
Fortis Healthcare Limited	-	173.56
Optionally convertible debentures		
Escorts Heart and Super Speciality Hospital Limited	2,649.45	6,090.29
Non-convertible debentures		
Fortis Healthcare Limited	7,062.50	14,360.41
Capital creditors		
Acibadem Teknoloji A.S	98.55	115.86
Trade and other payables		
Agilus Diagnostics Limited	1487.66	1,258.87
Fortis Healthcare Limited	580.63	53.54
Fortis Hospitals Limited	273.07	-
Hiranandani Healthcare Private Limited	0.80	0.39
Fortis Hospotel Limited	43.05	68.23
Fortis Health Management Limited	0.44	0.27
Fortis C-Doc Healthcare Limited	-	1.37
Stellant Capital Advisory Services Private Limited	13.79	11.72

- D.** As per the HMSA arrangement with the hospital operating company, the Company receives service fee consideration from the Hospital operating company, as an when due. As per terms of the HMSA, in the event of any delay in payment of the Service Fee, an interest at a rate of State Bank of India base rate plus 2% per annum (on a compounded monthly basis) shall be payable by hospital operating company to the Company. The Company and hospital operating company have agreed that no interest would be charged/demanded for the delay in the payments on amounts under HMSA for the financial year 2024-25 and 2025-26. Consequently, the Company has not recognised interest on the delayed payment of the service fees/technology renewal fund during the year ended March 31, 2025, and March 31, 2026.
- E.** All outstanding balances with these related parties are priced on an arm's length basis and are to be settled in cash within credit period from the reporting date. None of the balances are secured.
- F.** Amount shown is inclusive of perquisites, employee contribution to provident fund and excluding reimbursements of expenses.

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

7. Leases

(a) As a lessee

Information about leases for which the Company is a lessee is presented below:

(Amount in ₹ lacs)

Right-of-use assets	Leasehold Land	Building	Medical Equipment	Total
Gross carrying amount				
As at April 01, 2024 (refer note 24)	7,655.95	530.27	1,646.18	9,832.40
Addition for the year	-	-	-	-
De-recognition for the year	-	(130.95)	-	(130.95)
As at March 31, 2025	7,655.95	399.32	1,646.18	9,701.45
Addition for the year (refer note 23)	3,118.50	36,740.02	-	39,858.52
De-recognition for the year	-	-	-	-
As at March 31, 2026	10,774.45	37,139.34	1,646.18	49,559.97
Accumulated amortization				
As at April 01, 2024 (refer note 24)	508.77	379.25	254.00	1,142.02
Charge for the year	101.72	99.77	279.33	480.82
De-recognition for the year	-	(130.95)	-	(130.95)
As at March 31, 2025	610.49	348.07	533.33	1,491.89
Charge for the year	163.09	1,496.16	274.36	1,933.61
De-recognition for the year	-	-	-	-
As at March 31, 2026	773.58	1,844.23	807.69	3,425.51
Carrying value				
As at March 31, 2025	7,045.46	51.25	1,112.85	8,209.56
As at March 31, 2026	10,000.87	35,295.11	838.49	46,134.46

Lease Liabilities	Year ended March 31, 2026	Year ended March 31, 2025 (Restated)
Maturity analysis - contractual undiscounted cash flows		
Less than one years	3,427.18	441.49
One to five years	17,380.28	1,292.56
More than five years	41,742.04	-
Total undiscounted lease liabilities	62,549.50	1,734.05

Lease Liabilities included in the Balance Sheet	As at March 31, 2026	As at March 31, 2025 (Restated)
Current	621.07	326.43
Non-current	34,212.48	1,108.40

Amounts recognized in Statement of Profit and Loss	Year ended March 31, 2026	Year ended March 31, 2025 (Restated)
Interest on lease liabilities	1,744.55	146.48
Expenses relating to short-term leases and leases of low-value assets not included in the measurement of lease liabilities	2,025.17	1,338.07

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Amounts recognized in Statement of Cash Flows	Year ended March 31, 2026	Year ended March 31, 2025 (Restated)
Cash outflow for leases	443.27	333.32
Interest on lease liabilities (included in finance costs paid)	1,744.55	146.48
Total cash outflow for leases	2,187.82	479.80

(b) As a lessor

(i) Assets given on operating lease

The Company has sub- leased some portion of hospital premises carrying value of which included in leasehold land (refer note above) & freehold land/buildings (refer note 5(i)(a)). In all the cases, the agreements are further renewable at the option of the Company. The total lease payment received/receivable in respect of the above leases recognised in statement of profit and loss for the year are ₹ 512.39 lacs (March 31, 2025: ₹ 327.95 lacs).

(ii) Revenue from HMSA

The Company has entered into a Hospital and Medical Services Agreement (HMSA) with Hospital operating company wherein the Company is required to provide and maintain the Company's Clinical Establishments along with other services like out-patient diagnostics and radio diagnostic etc. The term of the individual HMSA is 15 years and the Company is entitled to receive composite service fee i.e. base and variable fee. The base fee is fixed and the variable fee is based on a percentage of hospital operating companies' net operating revenue, in accordance with the HMSA.

Future minimum base fee receivable at the end of the reporting period is as follows:

(Amount in ₹ lacs)

Particulars	Year ended March 31, 2026	Year ended March 31, 2025 (Restated)
Minimum service fee		
Less than one year	3,789.03	3,678.67
One to five years	2,121.05	5,910.08
More than five years	-	-
Total	5,910.08	9,588.75

8. Commitments

(Amount in ₹ lacs)

Particulars	As at March 31, 2026	As at March 31, 2025 (Restated)
Estimated amount of contracts remaining to be executed on capital account and not provided for		
- Property, plant and equipment (Net of capital advances of ₹405.54 lacs (₹291.16 lacs as of March 31, 2025))	6,582.22	9,178.16
- Intangible Asset	28.33	75.52
Total	6,610.55	9,253.68

The Company has other commitments for purchase orders which are issued after considering requirements as per operating cycle. The Company does not have any long-term commitments or material non-cancellable contractual commitments/contracts, for which there were any material foreseeable losses.

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

9. Borrowings

Secured borrowings

(Amount in ₹ lacs)

Particulars	Note	March 31, 2026		March 31, 2025 (Restated)	
		Non-Current	Current	Non-Current	Current
Term Loan from HSBC Bank	(i)	-	-	371.31	59.45
Term Loan from Axis Bank	(ii)	-	-	11,221.53	2,160.49
Term Loan from ICICI Bank	(iii)	-	-	5,887.83	939.15
Vehicle Loan from ICICI Bank	(v)	108.72	60.86	81.46	48.83
Vehicle Loan from Axis Bank	(vi)	33.04	10.14	-	-
Overdraft from HSBC Bank	(vii)	-	-	-	721.85
Overdraft from Axis Bank	(viii)	-	-	-	5.84
Overdraft from ICICI Bank	(ix)	-	-	-	18.74
Total		141.76	71.00	17,562.13	3,954.35

Unsecured borrowings

(Amount in ₹ lacs)

Particulars	Note	March 31, 2026		March 31, 2025 (Restated)	
		Non-Current	Current	Non-Current	Current
Term Loan from Axis Bank	(ii)	11,439.86	3,729.22	-	-
Term Loan from Mizuho	(iv)	12,757.89	-	-	-
Overdraft from HSBC Bank	(vii)	-	751.23	-	-
NCD issued to FHL	(x)	-	12,050.00	-	12,050.00
NCD issued to FHL	(xi)	-	12,960.00	-	12,960.00
NCD issued to FHL	(xii)	-	750.00	-	750.00
NCD issued to FHL	(xiii)	-	17,000.00	-	17,000.00
NCD issued to FHTL	(xiv)	46,716.77	-	46,716.77	-
OCD issued to EHSSHL	(xv)	-	-	-	-
CCD issued to FHL	(xvi)	-	-	-	-
Total		70,914.52	47,240.45	46,716.77	42,760.00

Notes:

- Term Loans carry an interest rate from 6.90 % p.a. to 7.20% p.a. (previous year 8.10% p.a. to 8.20%)
- Vehicle Loans carry an interest rate from 8.20% p.a. to 8.50% p.a. (previous year 7.50% p.a. to 9.10%)
- Overdraft / Working Capital Demand Loans carry an interest rate from 7.40% p.a. to 7.50% p.a. (previous year 9.10% p.a. to 9.20%).

(i) Term loan from The Hongkong and Shanghai Banking Corporation Limited (HSBC)

Allocation of borrowings pursuant to composite scheme of arrangement (refer note 24)

(Amount in ₹ lacs)

Particulars	As at March 31, 2026	As at March 31, 2025 (Restated)
Principal amount (₹ in lacs)	-	430.76

Pursuant to composite scheme of arrangement (refer note 24) ₹ 591.70 lacs term loan Term Loan facility from The Hongkong and Shanghai Banking Corporation Limited (“HSBC”) was allocated from FHsL to the company as at April 01, 2023. The Term loan facility from HSBC was secured against the exclusive charge on certain immoveable fixed assets of IHL (Noida and Faridabad), FHTL (Gurugram) and HEPL (Ludhiana, Mall Road) with minimum assets cover of 1.25x. During the current year, the Term Loan facility has been fully prepaid.

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(ii) Term loan from Axis Bank Limited

Particulars	As at March 31, 2026	As at March 31, 2025 (Restated)
Principal amount (₹ in lacs)	15,168.86	10,943.24
Accrued interest (₹ in lacs)	-	-

The Company has availed term loan facility from Axis bank in the previous years. The facility was secured by exclusive charge over immovable fixed assets of International Hospital Limited (immovable property situated in Bannerghata Road) with a security cover of minimum 1.1x (previous year 1.25x). The charge over the facility was withdrawn by the bank during the year, resulting in the facility being unsecured as at the March 31, 2026.

Balance outstanding against the term loan as on March 31, 2026 is ₹ 15,168.86 lacs (as on March 2025 is ₹ 10,943.24 lacs) of which ₹ 1,717.45 lacs was repayable in structured installment starting from May 2026 till June 2029 and ₹ 13,451.41 lacs is repayable in equal quarterly installments starting from June 2026 till September 2030.

Transfer of borrowings pursuant to composite scheme of arrangement (refer note 24)

Particulars	As at March 31, 2026	As at March 31, 2025 (Restated)
Principal amount (₹ in lacs)	-	2,438.78

Pursuant to composite scheme of arrangement (refer note 24) ₹ 2,438.78 lacs the Term Loan facility from Axis was allocated from FHsL to the Company as at April 01, 2023. The Term Loan facility was secured by second pari-passu charge over all the existing and future current assets of the FHsL and second pari-passu charge over movable fixed assets of the FHsL both present and future, excluding vehicles and medical equipment exclusively financed by other lenders. During the current year, the Term Loan facility got prepaid.

(iii) Term loan from ICICI Bank

Transfer of borrowings pursuant to composite scheme of arrangement (refer note 24)

Particulars	As at March 31, 2026	As at March 31, 2025 (Restated)
Principal amount (₹ in lacs)	-	6,826.98

Pursuant to composite scheme of arrangement (refer note 24) the Term Loan facility from ICICI Bank Limited (ICICI) was allocated from FHsL to the Company as at April 01, 2023. The Term Loan facility was secured against the first pari-passu charge on all moveable fixed and current assets of FHsL and exclusive charge on immovable fixed assets of the FHsL (Ludhiana hospital, Chandigarh Road, - Land & Building). During the current year, the Term Loan facility got prepaid.

(iv) Term Loan from Mizuho

Particulars	As at March 31, 2026	As at March 31, 2025 (Restated)
Principal amount (₹ in lacs)	12,757.89	-
Accrued interest (₹ in lacs)	-	-

During the year, the Company has taken term loan facility from Mizuho Financial Corporation which is unsecured. Repayable in two annual installments of ₹ 3,189.47 lacs and ₹ 9,568.42 lacs at the end of 48 months and 60 months respectively from the month of drawdown.

- (v) During the current year, the Company financed vehicle loans from ICICI bank which is secured against hypothecation of the vehicle financed. The loans are repayable in equated monthly installments over four years. As on March 31, 2026, the outstanding balance of vehicle loan is ₹ 13.12 lacs.

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Further, pursuant to composite scheme of arrangement (refer note 24), vehicle loans from ICICI bank were transferred from FHsL to the Company as on April 01, 2023 of ₹ 72.01 lacs, in accordance with scheme. These loans are secured against hypothecation of the vehicle financed. The loans are repayable in equated monthly installments over four years. As on March 31, 2026, the outstanding balance of this vehicle loan is ₹ 156.46 lacs (as at March 31, 2025 ₹ 130.29).

- (vi) During the current year, the Company financed vehicle loans from Axis bank which is secured against hypothecation of the vehicle financed. The loans are repayable in equated monthly installments over four years. As on March 31, 2026, the outstanding balance of vehicle loan is ₹ 43.18 lacs.
- (vii) During the previous year, the overdraft facility was secured by first pari passu charge over movable fixed assets of the Company both present and future, except the machinery and vehicles specifically financed by other banks or financial institutions and first pari-passu charge on current assets of the Company both present and future. During the current year, the overdraft facility from HSBC has become unsecured.

Further, pursuant to composite scheme of arrangement (refer note 24), bank overdraft from HSBC of ₹ 1,334.25 lacs was allocated from FHsL to the Company as on April 1, 2023, in accordance with scheme.

As on March 31, 2026, the outstanding balance of this overdraft is ₹ 751.23 lacs (as at March 31, 2025 ₹ 721.85 lacs).

- (viii) During the previous year, the overdraft facility was secured by first pari passu charge over current assets and moveable fixed assets of the Company, excluding vehicles and medical equipment exclusively financed by other lenders. During the Current year, the overdraft facility from Axis Bank has become unsecured.

As on March 31, 2026, the outstanding balance of overdraft is ₹ NIL (as at March 31, 2025 ₹ 5.84 lacs).

- (ix) Pursuant to composite scheme of arrangement (refer note 24), bank overdraft from ICICI were transferred from FHsL to IHL, in accordance with scheme. This overdraft facility was secured against the first pari-passu over moveable fixed assets of the FHsL both present and future except the machinery, vehicles specifically financed by other bank / Financial institutions and first pari-passu charge on current assets of the FHsL both present and future.

As on March 31, 2026, the outstanding balance of this overdraft is ₹ NIL (as at March 31, 2025 ₹ 18.74 lacs)

(x) Non-Convertible Debentures (NCDs)

- A. The Company had issued NCDs to RHT Health Trust Services Pte. Limited on October 14, 2015. On January 15, 2019 RHT Health Trust Services Pte. Limited sold these NCDs to Fortis Healthcare Limited. The details are as follows:

Particulars	As at March 31, 2026	As at March 31, 2025 (Restated)
Number of NCDs	1,205,000	1,205,000
Principal amount outstanding (₹ in lacs)	12,050.00	12,050.00
Accrued interest (₹ in lacs)	2,358.74	5,764.09
Payment made against accrued interest (₹ in lacs)	4,956.18	3,584.01
Rate of interest (p.a.)	14.30%	14.30%
Terms of redemption	The maturity date of NCDs is October 13, 2033.	

- B. The principal amount of NCDs is repayable on October 13, 2033 and interest on NCDs is payable on the half yearly basis i.e. April and October of every year.

As per the terms of the amended agreement dated July 12, 2017, consequent to the default in payment of interest, the outstanding principal and interest is repayable on demand. During the year ended March 31, 2019 the Company defaulted in payment of interest.

The Board of Directors of Fortis Healthcare Limited had during the earlier year confirmed through an extension letter that they will not call for the outstanding interest or/and principal till the time, the Company is in a position to make these payments. However, the Company does not have an substantial right to defer the payment for 12

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

months from reporting date in case demanded by Fortis Healthcare Limited and accordingly these have been classified as current.

xi) Non-Convertible Debentures (NCDs)

- A. The Company had issued NCDs to RHT Health Trust Services Pte. Limited on October 14, 2016. On January 15, 2019 RHT Health Trust Services Pte. Limited sold these NCDs to Fortis Healthcare Limited. The details are as follows:

Particulars	As at March 31, 2026	As at March 31, 2025 (Restated)
Number of NCDs	1,296,000	1,296,000
Principal amount outstanding (₹ lacs)	12,960.00	12,960.00
Accrued interest (₹ lacs)	2,004.42	3,163.31
Payment made against accrued interest (₹ in lacs)	2,815.18	1,281.96
Rate of interest (p.a.)	14.20%	14.20%
Terms of redemption	The maturity date of NCDs is October 13, 2034.	

- B. The principal amount of NCD is repayable on October 13, 2034 and the interest on NCDs is payable on the half yearly basis i.e. April and October of every year.

As per the terms of the amended agreement dated July 12, 2017, consequent to the default in payment of interest, the outstanding principal and interest is repayable on demand. During the year ended March 31, 2019, the Company had defaulted in payment of interest.

The Board of Directors of Fortis Healthcare Limited had during the earlier year confirmed through an extension letter that they will not call for the outstanding interest or/and principal till the time, the Company is in a position to make these payments. However, the Company does not have an substantial right to defer the payment for 12 months from reporting date in case demanded by Fortis Healthcare Limited and accordingly these have been classified as current.

xii) Non-Convertible Debentures (NCDs)

- A. The Company had issued NCDs to RHT Health Trust Services Pte. Limited on January 12, 2017. On January 15, 2019 RHT Health Trust Services Pte. Limited sold these NCDs to Fortis Healthcare Limited. The details are as follows:

Particulars	As at March 31, 2026	As at March 31, 2025 (Restated)
Number of NCDs	75,000	75,000
Principal amount outstanding (₹ in lacs)	750.00	750.00
Accrued interest (₹ in lacs)	126.17	339.89
Payment made against accrued interest (₹ in lacs)	302.48	213.62
Rate of interest (p.a.)	13.15%	13.15%
Terms of redemption	The maturity date of NCDs is January 11, 2035.	

- B. The principal amount of NCD is repayable on January 11, 2035 and the interest on NCDs is payable on the half yearly basis i.e. January and July of every year.

As per the terms of the amended agreement dated July 12, 2017, consequent to the default in payment of interest, the outstanding principal and interest is repayable on demand. During the year ended March 31, 2019, the Company had defaulted in payment of interest.

The Board of Directors of Fortis Healthcare Limited had during the earlier year confirmed through an extension letter that they will not call for the outstanding interest or/and principal till the time, the Company is in a position to make these payments. However, the Company does not have an substantial right to defer the payment for 12 months from reporting date in case demanded by Fortis Healthcare Limited and accordingly these have been classified as current.

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

xiii) Non-Convertible Debentures (NCDs)

- A. The Company had issued NCDs to RHT Health Trust Services Pte. Limited on October 24, 2017. On January 15, 2019 RHT Health Trust Services Pte. Limited sold these NCDs to Fortis Healthcare Limited. The details are as follows:

Particulars	As at March 31, 2026	As at March 31, 2025 (Restated)
Number of NCDs	1,700,000	1,700,000
Principal amount outstanding (₹ in lacs)	17,000	17,000
Accrued interest (₹ in lacs)	2,573.16	5,093.12
Payment made against accrued interest (₹ in lacs)	4,532.61	2,620.41
Rate of interest (p.a.)	13.15%	13.15%
Terms of redemption	The maturity date of NCDs is October 23, 2035.	

- B. The principal amount of NCD is repayable on October 23, 2035 and the interest on NCDs is payable on the half yearly basis i.e. Oct and April of every year.
As per the terms of the agreement, consequent to the default in payment of interest, the outstanding principal and interest is repayable on demand. During the year ended March 31, 2019, the Company had defaulted in payment of interest.

The Board of Directors of Fortis Healthcare Limited had during the earlier year confirmed through an extension letter that they will not call for the outstanding interest or/and principal till the time, the Company is in a position to make these payments. However, the Company does not have a substantial right to defer the payment for 12 months from reporting date in case demanded by Fortis Healthcare Limited and accordingly these have been classified as current.

xiv) Non-convertible debentures (NCDs) issued to Fortis Hospotel Limited (FHTL)

The Company had issued NCDs to Fortis Hospotel Limited on October 14, 2016. The details are as follows:

Particulars	As at March 31, 2026	As at March 31, 2025 (Restated)
Number of NCDs	4,671,677	4,671,677
Principal amount outstanding (₹ lacs)	46,716.77	46,716.77
Accrued interest (₹ lacs)	36,345.62	31,339.83
Rate of interest* (p.a.)	9.30%	9.30%
Redemption date	October 12, 2031	October 14, 2026

*These NCDs carry floating rate of interest based on the performance of the Company as below:

Sr. No.	Level of EBIT	Rate of Interest
1	Less than 3,000 Crore	9.30% p.a.
2	3,000 Crore to 3,250 Crore	18% p.a., provided additional 8.7% p.a. from closing date to the beginning of the year for which EBIT is more than 3,000 Crore
3	3,250 Crore to 3,500 Crore	20% p.a., provided additional 2% p.a. from closing date to the beginning of the year for which EBIT is more than 3,250 Crore
4	more than 3,500 Crore	22% p.a., provided additional 2% p.a. from closing date to the beginning of the year for which EBIT is more than 3,500 Crore

The interest accrued on the above NCDs is payable at the time of maturity or at early repayment date, as mutually agreed between the parties.

xv) Optionally convertible debentures (OCDs) issued to Escorts Heart and Super Speciality Hospital Limited (EHSSHL)

- A. The Company issued OCDs to Escorts Heart and Super Speciality Hospital Limited on September 17, 2012. The details are as follows:

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Particulars	As at March 31, 2026	As at March 31, 2025 (Restated)
Number of OCDs	-	-
Principal amount outstanding (₹ in lacs)	-	-
Accrued interest (₹ in lacs)	2,649.45	6,090.29
Payment made against principal (₹ in lacs)	-	17,775.00
Payment made against accrued interest (₹ in lacs)	3,440.84	1,397.00
Rate of interest (p.a.)	9.00%	9.00%
Redemption	The maturity date of OCDs was September 16, 2030 or earlier by giving a six-month notice	

These OCDs carry floating rate of interest based on the performance of the Company as below:

Sr. No.	Level of EBIT	Rate of Interest
1	Less than 3,000 Crore	9% p.a.
2	3,000 Crore to 3,250 Crore	18% p.a., provided additional 8.7% p.a. from closing date to the beginning of the year for which EBIT is more than 3,000 Crore
3	3,250 Crore to 3,500 Crore	20% p.a., provided additional 2% p.a. from closing date to the beginning of the year for which EBIT is more than 3,250 Crore
4	more than 3,500 Crore	22% p.a., provided additional 2% p.a. from closing date to the beginning of the year for which EBIT is more than 3,500 Crore

- B. In case of these OCDs, only the lender had the option to convert the outstanding amount into the equity shares of the Company. Also, both the parties had option to early redeem the debentures by giving six months' notice. The interest on OCDs is payable on monthly basis or can be deferred upto a period of five years on a mutually agreed basis which has already been expired.

During the year ended March 31, 2019, the Company had defaulted in payment of interest.

The Board of Directors of Escorts Heart and Super Speciality Hospital Limited had confirmed through an extension letter that they will not call for the outstanding interest or/and principal till the time, the Company is in a position to make these payments. However, the Company does not have an unconditional right to defer the payment in case demanded by Escorts Heart and Super Speciality Hospital Limited and accordingly these have been classified as current.

During the previous year, the Company has repaid the outstanding principal of ₹ 17,775.00 lacs to EHSSHL.

xvi) Compulsorily convertible debentures (CCDs)

The Company in earlier years issued CCDs to Fortis Global Healthcare Infrastructure Pte. Limited (FGHIPL) in three tranches. The same were transferred to Fortis Healthcare Limited (FHL) on January 15, 2019. The details of these CCDs are as follows:

Sr. No.	Number of CCDs	Aggregate consideration of CCDs (₹ in lacs)	Interest rate (p.a.) payable quarterly	No. of equity shares issued upon conversion
1	6,508,000	65,080	17.00%	14,526,785
2	330,000	3,300	16.75%	292,862
3	3,771,000	37,710	17.50%	3,689,824

During the year ended March 31, 2019, the Company had defaulted in payment of interest as per the terms of the agreement. As per the agreement, consequent to the default in payment of interest, the outstanding interest is repayable on demand. On March 29, 2019, the Board of Directors of the Company passed a resolution to convert these CCDs into equity shares. However, interest accrued till the date of conversion has not been paid by the Company. The outstanding amount of such interest as included in other current financial liabilities amounts to Nil (as on March 31, 2025: ₹ 173.56 Lakhs).

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

10. Employee benefit plans

(a) Defined contribution plan

Under the defined contribution plans, the Company makes provident funds (PF) and employee state insurance (ESI) contributions for qualifying employees. The Company's contribution to the Employees Provident Fund is deposited with regional Provident Fund Commissioner which is recognized by Income Tax authorities. The Contribution payable to the plan by the Company is at the rate specified in the rules. During the year, the Company has recognized the following amounts in the statement of profit and loss under the defined contribution plans:

Particulars	(Amount in ₹ lacs)	
	For the year ended March 31, 2026	For the year ended March 31, 2025 (Restated)
Contribution to provident fund	1,243.99	1,052.55
Contribution to employee state insurance	64.99	44.76
Total expense	1,308.98	1,097.31

(b) Defined benefit plan

Gratuity

The Company has a defined benefit gratuity plan, where each employee who has completed five years or more (one year for fixed term employee) of service gets a gratuity on departure at 15 days wages for each completed year of service. Vesting occurs upon completion of 5 years of service for regular employees and 1 year for fixed term employees.

The following table summarizes the components of net benefit expenses recognized in the Statement of Profit and Loss and the amounts recognized in the Balance Sheet.

Particulars	As at		As at	
	March 31, 2026		March 31, 2025 (Restated)	
	Gratuity (Unfunded)	Gratuity (Funded)	Gratuity (Unfunded)	Gratuity (Funded)
i. Changes in present value of the defined benefit obligation are as follows:				
Present value of obligation at the beginning of the year (refer note 24)	2,800.20	574.98	2,301.53	499.85
Current service cost	416.12	59.33	292.87	47.52
Interest cost	202.68	37.69	155.94	32.15
Past Service cost	732.41	96.15	-	-
Actuarial (gain) /loss recognized in other comprehensive income	24.11	(20.12)	191.81	76.50
Acquisition cost {transfers in/(out)}	47.84	(8.09)	(1.60)	-
Benefits paid	(210.10)	(21.50)	(140.35)	(81.04)
Present value of obligations at the end of the year	4,013.26	718.44	2,800.20	574.98
Amounts in the Balance Sheet				
(a) Liabilities	4,013.26	718.44	2,800.20	574.98
(b) Assets	-	(36.01)	-	(54.01)
(c) Net liability/(asset) recognized in the balance sheet	4,013.26	682.43	2,800.20	520.97
- Current Liability	239.27	-	146.66	-
- Non-Current Liability	3,773.99	682.43	2,653.54	520.97

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(Amount in ₹ lacs)

Particulars	As at March 31, 2026	As at March 31, 2025 (Restated)
	Gratuity (Funded)	Gratuity (Funded)
ii. Changes in fair value of assets are as follows:		
Opening fair value of plan assets	54.01	102.74
Interest in income on plan assets	2.83	5.23
Expected return	0.33	2.42
Contribution by employer	-	25.00
Benefits paid	(21.16)	(81.38)
Closing fair value of plan assets	36.01	54.01

(Amount in ₹ lacs)

iii. Expense recognized in Statement of Profit and Loss is as follows:	Year ended		Year ended (Restated)	
	March 31, 2026		March 31, 2025	
	Gratuity (Unfunded)	Gratuity (Funded)	Gratuity (Unfunded)	Gratuity (Funded)
Amount recognized in employee benefit expense				
Current Service cost	416.12	59.33	292.87	47.52
Total	416.12	59.33	292.87	47.52
Amount recognized in finance costs				
Net interest cost	202.68	34.86	155.94	26.92
Total	202.68	34.86	155.94	26.92
Amount recognized in exceptional items				
Past service cost	732.41	96.15	-	-
Total	732.41	96.15	-	-
Total amount charged to Statement to Profit and Loss	1,351.21	190.34	448.81	74.44

(Amount in ₹ lacs)

iv. Expense recognised in Statement of Other comprehensive income is as follows:	Year ended		Year ended (Restated)	
	March 31, 2026		March 31, 2025	
	Gratuity (Unfunded)	Gratuity (Funded)	Gratuity (Unfunded)	Gratuity (Funded)
Net actuarial loss / (gain) due to experience adjustment	24.11	(20.12)	191.81	76.50
Return on plan assets (greater)/less than discount rate	-	(0.33)	-	(2.42)
	24.11	(20.45)	191.81	74.08

The principal assumptions used in determining gratuity and compensated absences obligation for the Company's plan is shown below:

(i) In case of following locations (Anandpur, FHKI, Mulund and Kalyan): -

Principal actuarial assumptions for gratuity and compensated absences	As at March 31, 2026	As at March 31, 2025 (Restated)
	(Unfunded)	(Unfunded)
Discounting rate (p.a.)	6.75%	6.50%
Expected salary increase rate (p.a.)	8.00%	8.00%
Withdrawal rate		
Age up to 30 years	10.00% - 30.00%	10.00% - 30.00%
Age from 31 to 40 years	5.00% - 25.00%	5.00% - 25.00%
Age from 41 to 50 years	3.00% - 15.00%	3.00% - 15.00%
Age above 50 years	2.00% - 10.00%	1.00% - 10.00%

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Principal actuarial assumptions for gratuity and compensated absences	As at March 31, 2026	As at March 31, 2025 (Restated)
	(Unfunded)	(Unfunded)
Mortality table used	Indian Assured Lives Mortality (2006-08)	Indian Assured Lives Mortality (2006-08)

(ii) In case of other locations: -

Principal actuarial assumptions for gratuity and compensated absences	As at March 31, 2026		As at March 31, 2025 (Restated)	
	(Unfunded)	(Funded)	(Unfunded)	(Funded)
Discounting rate (p.a.)	6.75%	6.75%	7.00%-7.25%	7.25%
Expected rate of return on plan assets (p.a.)	-	6.75%	-	7.25%
Expected salary increase rate (p.a.)	7.50%-8.00%	7.50%	7.50%-8.00%	7.50%
Withdrawal rate				
Age up to 30 years	18%	18%	18%	18%
Age from 31 to 44 years	6%	6%	6%	6%
Age above 44 years	2%	2%	2%	2%
Mortality table used	Indian Assured Lives Mortality (2006-08)	Indian Assured Lives Mortality (2006-08)	Indian Assured Lives Mortality (2006-08)	Indian Assured Lives Mortality (2006-08)

Notes:

- The estimates of future salary increase, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.
- Significant actuarial assumption for the determination of the defined obligation are discount rate, expected salary escalation rate and withdrawal rate. The sensitivity analyses below have been determined by the actuarial based on reasonably possible changes of the respective assumption occurring at the end of the reporting period, while holding all other assumptions constant.

Particulars	Year ended March 31, 2026		Year ended March 31, 2025 (Restated)	
	Increase	Decrease	Increase	Decrease
Change in discount rate by 0.50%	(197.51)	212.52	(146.34)	157.65
Change in salary escalation rate by 1%	433.39	(381.77)	320.84	(282.09)
Change in withdrawal rate by 5%	(159.15)	169.85	(135.53)	146.19

Expected benefit payments for the future years

(Amount in ₹ lacs)					
Year ended March 31, 2027	Year ended March 31, 2028	Year ended March 31, 2029	Year ended March 31, 2030	Year ended March 31, 2031	Year ended March 31, 2032 to year ended March 31, 2036
318.10	343.01	643.51	462.44	567.91	3,367.78

As at March 31, 2026 the weighted average duration of defined benefit obligation was 9 years (March 31, 2025: 9 years)

11. Financial Instruments

i) Capital Management

The Company manages its capital to ensure that the Company will be able to continue as going concern while maximizing the return to stakeholders through the optimization of the debt and equity balance.

The capital structure of the Company consists of net debt (borrowings as detailed in notes 5(xv), 5(xvi), and 7(a)) and total equity of the Company.

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

The Company is not subject to any externally imposed capital requirements other than for covenants under various loan arrangements of the Company.

The Company's Board reviews the capital structure of the Company on need basis. As part of this review, the Board considers the cost of capital and the risks associated with each class of capital.

Amongst other things, the Company's objective for capital management is to ensure that it maintains stable capital management by monitoring the financial covenants attached to the interest-bearing loans and borrowings. The gearing ratio at March 31, 2026 and March 31, 2025 is as follows:

Gearing ratio

The gearing ratio at end of the reporting period was as follows:

Particulars	(Amount in ₹ lacs)	
	As at March 31, 2026	As at March 31, 2025 (Restated)
Debt*	199,276.76	164,401.50
Less: Cash and cash equivalents [Refer note 5(xii)(a)]	(1,066.55)	(194.06)
Net debt	198,210.21	164,207.44
Total equity	239,031.86	208,777.70
Net debt to equity ratio	82.92%	78.65%

*Debt is defined as long-term and short-term borrowings (including interest accrued on borrowings, lease liabilities and excluding, financial guarantee contracts and contingent consideration).

(ii) Financial risk management objectives

The Company's Corporate Treasury function provides services to the business, co-ordinates access to domestic and international financial markets, monitors and manages the financial risks including market risk (including interest rate risk and other price risk), credit risk and liquidity risk.

The Board of Directors manages the financial risk of the Company through internal risk reports which analyze exposure by magnitude of risk.

Market Risk

The Company's activities expose it primarily to the financial risks of changes in interest rates and foreign currency exchange rates.

a) Foreign currency risk management

The Company undertakes transactions denominated in foreign currencies; consequently, exposures to exchange rate fluctuations arise. Exchange rate exposures are managed within approved policy parameters.

The carrying amounts of the Company's foreign currency denominated monetary assets and monetary liabilities at the end of the reporting period are as follows.

Particulars	Currency	(Amount in ₹ lacs)			
		As at March 31, 2026		As at March 31, 2025 (Restated)	
		Foreign Currency in lacs	Equivalent Rupees in lacs	Foreign Currency in lacs	Equivalent Rupees in lacs
Advance from patients	USD	0.02	2.28	0.07	6.46
Trade receivables	USD	1.63	153.68	0.49	42.12
Cash in hand	USD	0.33	30.67	0.32	27.39
Trade payables	USD	0.32	30.05	-	-

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

b) Foreign currency sensitivity analysis

The Company is mainly exposed to fluctuations in USD currency.

The following table details the Company's sensitivity to a 5% increase and decrease in the Rupees against USD. 5% is the sensitivity rate used when reporting foreign currency risk internally to key management personnel and represents management's assessment of the reasonably possible change in foreign exchange rates. The sensitivity analysis includes only outstanding foreign currency denominated monetary items and adjusts their translation at the period end for a 5% change in foreign currency rates. This analysis assumes that all other variables, in particular interest rate to remain same. A positive number below indicates an increase in profit or equity where the Rupees. strengthens 5% against the relevant currency. For a 5% weakening of the Rupees against the relevant currency, there would be a comparable impact on the profit or equity, and the balances below would be negative.

(Amount in ₹ lacs)

If increases by 5%	Currency impact US	
	As at March 31, 2026	As at March 31, 2025
Particulars		
Impact on profit or loss for the year [(Increase)/decrease]	(7.83)	(3.15)
Impact on total equity as at the end of the reporting period	(5.87)	(2.36)

(Amount in ₹ lacs)

If decreases by 5%	Currency impact USD	
	As at March 31, 2026	As at March 31, 2025
Particulars		
Impact on profit or loss for the year [(Increase)/decrease]	7.83	3.15
Impact on total equity as at the end of the reporting period	5.87	2.36

c) Foreign exchange derivative and non derivative financial instrument

The Company uses derivative for hedging financial risks that arise from its commercial business activities. The group's corporate treasury team manages its foreign currency risk by hedging transactions that are expected to occur within 12 months for hedges of significant forecasted purchases and capital expenditure. When a derivative is entered into for the purpose of being a hedge, the Company negotiates the terms of those derivatives to match the terms of the hedged exposure. All identified exposures are managed as per the policy duly approved by the Board of Directors.

The following table details the foreign currency derivative contracts outstanding at the end of the reporting period:

Outstanding Contracts*	No. of Deals	Contract value of foreign Currency (Rs in lacs) *	Maturity	
			Up to 12 months Nominal Amount** (Rs. in lacs)	More than 12 months Nominal Amount* (Rs. in lacs)
			As at March 31, 2026	As at March 31, 2026
USD/INR Buy forward	2	267.06	266.79	-

*Computed using marked to market rate.

** Sensitivity on the above forward contracts in respect of foreign currency exposure is not material.

d) Interest rate risk management

The Company is exposed to interest rate risk because Company borrows funds at both fixed and floating interest rates. The risk is managed by the Company by maintaining an appropriate mix between fixed and floating rate borrowings.

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Interest rate sensitivity analysis

The sensitivity analyses below have been determined based on the exposure to interest rates at the end of the reporting period. For floating rate liabilities, the analysis is prepared assuming the amount of liability outstanding at the end of the reporting period was outstanding for the whole year. A 50-basis point increase or decrease is used when reporting interest rate risk internally to key management personnel and represents management's assessment of the reasonably possible change in interest rates.

(Amount in ₹ lacs)

If increase by 50 basis point	Interest impact	Interest impact
Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Increase / (decrease) in profit or loss before tax for the year	(143.39)	(106.93)
Increase / (decrease) in other equity	(107.31)	(80.02)

If decrease by 50 basis point	Interest impact	Interest impact
Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Increase / (decrease) in profit or loss before tax for the year	143.39	106.93
Increase / (decrease) in other equity	107.31	80.02

e) Other price risks

The Company investment are primarily in group companies and are held for strategic purposes rather than for trading purposes.

f) Credit risk management

Credit risk refers to the risk that a counter party will default on its contractual obligations resulting in financial loss to the Company. The Company takes due care while extending any credit as per the approval matrix approved by Board of Directors.

Refer note 5(v) of the financial statements for carrying amount and maximum credit risk exposure for trade receivables.

Expected credit loss on financial assets other than trade receivables:

Company carries other financial assets such as investments in fellow subsidiaries and interest accrued on such investments, security deposits, bank deposits and interest accrued thereon, balances with banks, loans to related parties and interest accrued thereon, other receivable etc. Company monitors the credit exposure on these financial assets on a case-to-case basis. Loans to fellow subsidiaries are assessed for credit risk based on the underlying valuation of the entity and their ability to repay within the contractual repayment terms. Company creates loss allowance wherever there is an indication that credit risk has increased significantly.

Reconciliation of loss allowance measured at life-time expected credit losses for credit impaired financial assets other than trade receivables

(Amount in ₹ lacs)

Particular of loss allowance	As at March 31, 2026	As at March 31, 2025
Balance at the beginning of the year (refer note 24)	5,972.18	5,925.92
Loss allowance recognized	41.78	46.26
Balance at the end of the year	6,013.96	5,972.18

g) Liquidity risk management

Ultimate responsibility for liquidity risk management rests with the board of directors. The Company manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by continuously monitoring forecast and actual cash flows, and by matching the maturity profiles of financial assets and liabilities. Note given below sets out details of additional undrawn facilities that the Company has at its disposal to further reduce liquidity risk.

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

As at March 31, 2026*

(Amount in ₹ lacs)

Particulars	Sanctioned limit	Undrawn limit
Axis Bank (term loan)	19,112.00	1,345.00
Mizuho (term loan)	15,000.00	2,200.00
HSBC Bank (overdraft facility)	5,000.00	4,248.77
Axis Bank (overdraft facility)	2,000.00	2,000.00
Mizuho (overdraft facility)	2,000.00	2,000.00

As at March 31, 2025*

(Amount in ₹ lacs)

Particulars	Sanctioned limit	Undrawn limit
HSBC Bank (term loan)	20,000.00	8,145.00
DBS Bank (term loan)	2,000.00	2,000.00
HSBC Bank (overdraft facility)	2,000.00	1,994.16

* excluding borrowings transferred from FHsL to IHL on account of scheme of arrangement (refer note 24)

Liquidity and interest risk tables

The following tables detail the Company's remaining contractual maturity for its non-derivative financial liabilities with agreed repayment periods. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the Company can be required to pay.

The tables include both interest and principal cash flows. To the extent that interest flows are floating rate, the undiscounted amount is derived from interest rate curves at the end of the reporting period.

(Amount in ₹ lacs)

Particulars	Within 1 year	1-2 years	More than 2 years	Total	Carrying amount
As at March 31, 2026					
Interest accrued on Optionally convertible debentures*	2,649.45	-	-	2,649.45	2,649.45
Non-convertible debentures (non-current) (including accrued interest)	-	-	104,785.69	104,785.69	83,062.39
Non-convertible debentures* (current) (including accrued interest)	55,720.10	-	-	55,720.10	49,822.50
Loan from bank (including accrued interest)	5,639.00	5,120.00	23,931.00	34,690.00	28,157.65
Bank Overdraft	751.23	-	-	751.23	751.23
Lease liabilities	3,427.18	17,380.28	41,742.04	62,549.50	34,833.55
Trade payables	27,248.33	-	-	27,248.33	27,248.35
Other financial liabilities – Current	5,876.50	-	-	5,876.50	5,876.50
Total	101,311.79	22,500.28	170,458.73	294,270.80	232,401.62

Particulars	Within 1 year	1-2 years	More than 2 years	Total	Carrying amount
As at March 31, 2025					
Interest accrued on Compulsorily convertible debentures*	173.56	-	-	173.56	173.56
Interest accrued on Optionally convertible debentures*	6,090.29	-	-	6,090.29	6,090.29
Non-convertible debentures (non-current) (including accrued interest)	-	-	104,125.64	104,125.64	78,056.60
Non-convertible debentures* (current) (including accrued interest)	63,018.01	-	-	63,018.01	57,120.41

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Particulars	Within 1 year	1-2 years	More than 2 years	Total	Carrying amount
Loan from bank (including accrued interest)	4,898.39	12,646.29	7,856.34	25,401.02	20,779.39
Bank Overdraft	746.42	-	-	746.42	746.42
Lease liabilities	441.49	368.16	924.4	1,734.05	1,434.83
Trade payables	21,553.17	-	-	21,553.17	21,553.17
Other financial liabilities – Current	6,467.78	-	-	6,467.78	6,467.78
Total	103,389.11	13,014.45	112,906.38	229,309.94	192,422.45

*The Board of Directors of the respective lenders have agreed that they will not call for the outstanding interest or/and principal till the time the Company is in a position to make these payments. Also refer note 9(i) to (xvi).

12. Fair value measurement

March 31, 2026

(Amount in ₹ lacs)

Particulars	Note	Carrying value			Fair value
		Fair value through profit and loss (FVTPL)	Amortized cost	Total	
Financial assets					
Investment in preference shares (including accrued interest)	(b)	-	46,865.21	46,865.21	46,865.21
Trade receivables	(a)	-	34,224.94	34,224.94	34,224.94
Cash and cash equivalents	(a)	-	1,066.55	1,066.55	1,066.55
Other bank balances	(a)	-	46.01	46.01	46.01
Security Deposits (Non-current)	(b)	-	3,970.78	3,970.78	3,970.78
Bank deposits (including accrued interest)	(a)	-	90.37	90.37	90.37
Other financial assets (current)	(a)	-	2,909.73	2,909.73	2,909.73
Derivative assets	(f)	0.27	-	0.27	0.27
Total		0.27	89,173.59	89,173.86	89,173.86
Financial Liabilities					
Loan from bank & bank overdraft	(c)	-	28,908.88	28,908.88	28,908.88
Lease liabilities	(d)	-	34,833.55	34,833.55	34,833.55
Interest accrued on optionally convertible debentures	(a)	-	2,649.46	2,649.46	2,649.46
Non-convertible debentures: current (including accrued interest)	(a)	-	49,822.50	49,822.50	49,822.50
Non-convertible debentures: non-current (including accrued interest)	(e)	-	83,062.39	83,062.39	83,062.39
Trade payable	(a)	-	27,248.35	27,248.35	27,248.35
Other financial liabilities (current)	(a)	-	5,876.50	5,876.50	5,876.50
Total		-	232,401.63	232,401.63	232,401.63

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

March 31, 2025 (Restated)

(Amount in ₹ lacs)

Particulars	Note	Carrying value			Fair value
		Fair value through profit and loss (FVTPL)	Amortized cost	Total	
Financial assets					
Investment in preference shares (including accrued interest)	(b)	-	42,055.80	42,055.80	42,055.80
Trade receivables	(a)	-	26,579.38	26,579.38	26,579.38
Cash and cash equivalents	(a)	-	194.06	194.06	194.06
Other bank balances	(a)	-	86.00	86.00	86.00
Intercompany loan to related parties, current and non-current (including accrued interest)	(a)/ (b)	-	194.76	194.76	194.76
Security Deposits (Non-current)	(b)	-	1,011.22	1,011.22	1,011.22
Bank deposits (including accrued interest)	(a)	-	30.36	30.36	30.36
Other financial assets (current)	(a)	-	35,647.32	35,647.32	35,647.32
Total		-	105,798.90	105,798.90	105,798.90
Financial Liabilities					
Loan from bank (including accrued interest) & bank overdraft	(c)	-	21,525.81	21,525.81	21,525.81
Lease liabilities	(d)	-	1,434.83	1,434.83	1,434.83
Optionally convertible debentures: (including accrued interest)	(a)	-	6,090.29	6,090.29	6,090.29
Non-convertible debentures: current (including accrued interest)	(a)	-	57,120.41	57,120.41	57,120.41
Non-convertible debentures: non-current (including accrued interest)	(e)	-	78,056.60	78,056.60	78,056.60
Interest accrued on liability component of compulsorily convertible debentures	(c)	-	173.56	173.56	173.56
Trade payable	(a)	-	21,553.17	21,553.17	21,553.17
Other financial liabilities (current)	(a)	-	6,467.78	6,467.78	6,467.78
Total		-	192,422.45	192,422.45	192,422.45

The following methods / assumptions were used to estimate the fair values:

- (a) Fair valuation of financial assets and liabilities with short term maturities is considered as approximate to respective carrying amount due to the short-term maturities of these instruments.
- (b) Fair valuation of non-current financial assets and liabilities has been disclosed to be same as carrying value as there is no significant difference between carrying value and fair value.
- (c) The Company's borrowings (excluding loan from holding Company and vehicle loans) have been primarily contracted at floating rates of interest, which resets at short intervals. Accordingly, the carrying value of such borrowings (including interest accrued but not due) approximates fair value.
- (d) Fair value measurement of lease liabilities is not required to be disclosed.
- (e) The fair value of non-convertible debentures (including interest accrued) is calculated based on cash flows discounted using the current borrowing rate. This is classified as Level 3 fair value in the fair value hierarchy due to the use of unobservable inputs.
- (f) The fair value of derivative assets / liability is based on the valuation as provided by bank.

There are no transfers between Level 1, Level 2 and Level 3 during the year ended March 31, 2026 and March 31, 2025.

The above table excludes investment in equity shares of subsidiaries and associates of ₹ 130,400.59 lacs (Previous year ₹ 103,174.83 lacs) which are shown at cost in balance sheet as per Ind AS 27 "Separate Financial Statements".

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

There are no financial instruments measured at fair value through Other Comprehensive Income.

13. Details of dues to Micro and Small Enterprises as per MSMED Act, 2006

The Ministry of Micro and Small Enterprises has issued an office memorandum dated August 26, 2008 which recommends that the micro enterprises and the small enterprises should mention in their correspondences with their customers the Entrepreneur Memorandum Number as allocated after filing of the memorandum. Accordingly, the below information regarding dues to Micro and Small Enterprises have been determined to the extent such parties have been identified based on information available with the Company:

Particulars	(Amount in ₹ lacs)	
	As at March 31, 2026	As at March 31, 2025 (Restated)
The principal amount and the interest due thereon remain unpaid to any supplier at the end of each accounting year:		
- Principal amount due to micro and small enterprises*	2,549.13	4,153.54
- Interest due on above	-	5.38
The amount of interest paid by the buyer in terms of section 16 of the MSMED Act 2006 along with the amounts of the payment made to the supplier beyond the appointed day during each accounting year	2,034.59	7,982.31
The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act 2006.	-	-
The amount of interest accrued and remaining unpaid at the end of the accounting year	5.38	5.38
The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under section 23 of the MSMED Act 2006	-	-

*This also includes amount due to capital creditors amounting ₹ 370.74 lacs (as on March 31, 2025 ₹ 1,723.17 lacs).

14. Segment reporting

The Company is primarily engaged in the business of healthcare services which is the only reportable segment as per Ind AS 108 "Operating Segments"

Sales by market- Revenue from external customers by location of customers

The following table shows the distribution of the Company's revenues by geographical market:

Particulars	(Amount in ₹ lacs)	
	Year ended March 31, 2026	Year ended March 31, 2025 (Restated)
India	248,394.72	208,298.51
Outside India	-	-
Total	248,394.72	208,298.51

Carrying value of non-current assets- by location of assets

The following table shows the carrying amount of non-current assets other than financial instruments by geographical area in which the assets are located:

Particulars	(Amount in ₹ lacs)	
	As at March 31, 2026	As at March 31, 2025 (Restated)
India	273,649.03	212,168.84
Outside India	-	-
Total	273,649.03	212,168.84

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

15. On January 9, 2026, as part of a composite transaction, the Company consummated the acquisition of TMI Healthcare Private Limited (TMI) which runs the 125-bedded 'People Tree Hospital, Yeshwanthpur, Bengaluru' (PTHY) along with the acquisition of the hospital building and the underlying land of PTHY from the promoters of TMI and an adjacent land parcel from an independent third party; for an cumulative value of Rupees 39,151 lacs (including Rupees 38,309 lacs settled in cash, stamp duty paid on registration of Rupees 842 lacs and excluding debt and debt like adjustment). This is subject to final working capital adjustments as agreed in the definitive agreements.

16. Contingent liabilities

Claims against the Company not acknowledged as debt

(Amount in ₹ lacs)

S. No.	Particulars	As at March 31, 2026*	As at March 31, 2025* (Restated)
1.	Income tax		
	- Disallowance of interest on CCDs and other matters (Refer note 1 below)	50,555.74	50,555.74
2.	Service tax	2,395.37	3,564.96
3.	Luxury tax	-	16.56
4.	VAT	3,397.09	2,166.55
5.	Medical negligence and related matters	7,286.19	3,822.51
6.	Others	186.32	188.50
		63,820.71	60,314.82

*Reflects litigation existed at balance sheet date.

The Company believes that none of the above matters, either individually or in aggregate, are expected to have any material adverse effect on its financial statements. The cash flows in respect of above matters are determinable only on receipt of judgements/decisions pending at various stages/forums.

Note 1: As per clause 7 of the sponsor agreement dated September 18, 2012, the Company is indemnified by Fortis Healthcare Limited (Holding Company) for any losses suffered or to be suffered arising from outstanding assessments/ litigations relating to non-allowance of interest on compulsorily convertible debentures or optionally convertible debentures. Based on the management's own assessment, the Company believes that the probability of an unfavorable outcome is not probable for the indemnified outstanding assessments/ litigations.

Note 2: On 28 February 2019, a judgment of the Supreme Court of India interpreting certain statutory defined contribution obligations of employees and employers (the "India Defined Contribution Obligation") altered historical understandings of such obligations, extending them to cover additional portions of the employee's income to measure obligations under employees Provident Fund Act, 1952. There are numerous interpretative issues relating to this judgement as to how the liability should be calculated, including the period of assessment, the application with respect to certain current and former employees and whether interest and penalties may be assessed. As such, the Company has been legally advised not to consider that there is any probable obligations for periods prior to date of aforesaid judgment.

Note 3: Company has assessed that it is only possible, but not probable, that outflow of economic resources will be required.

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

17. Disclosure as per Section 186 (4) of Companies Act, 2013

- i) The particulars of the loan given by the Company for the purpose of business expansion as required to be disclosed by Section 186 (4) of Companies Act, 2013 are as follows:

(Amount in ₹ lacs)

Name of the party	Rate of Interest/ Premium on redemption	Redemption/ Termination date	Secured/ unsecured	Maximum Amount Outstanding		Closing Balance	
				31 March 2026	31 March 2025	31 March 2026	31 March 2025
Hospitalia Eastern Private Limited [Note 1]	8.21% p.a. (March 31, 2025: 9.05% p.a.)	March 31, 2026	Unsecured	120.00	120.00	-	120.00

Note 1: During the year ended March 31, 2019, Hospitalia Eastern Private Limited continued with the default in the payment of amount of principal and interest. As per the amended agreement, consequent to the default, the outstanding receivable on account of principal and interest are receivable on demand. Further, the agreement had been extended to 31 March 2026. Further, the board of director of the Company have agreed that they will not call for the outstanding principal till the time, Hospitalia Eastern Private Limited is in a position to make these payments.

The amount has been repaid during the current year.

- ii) The particulars of the investments in equity shares by the Company for the purpose of business expansion as required to be disclosed by Section 186 (4) of Companies Act, 2013 are as follows:

(Amount in ₹ lacs)

Issuer's name	Redemption/ Termination date	Secured/ Unsecured	Investment Amount outstanding amount as at	
			March 31, 2026	March 31, 2025
Escorts Heart and Super Specialty Hospital Limited	NA	Unsecured	1,298.94	1,298.94
Fortis Health Management Limited	NA	Unsecured	1,156.88	1,156.88
Renew Wind Energy AP Private Limited	At the time of termination of agreement	Unsecured	12.30	12.30
TMI Healthcare Private Limited	NA	Unsecured	27,225.75	-

- iii) The particulars of the investments in redeemable preference shares by the Company for the purpose of business expansion as required to be disclosed by Section 186 (4) of Companies Act, 2013 are as follows:

(Amount in ₹ lacs)

Issuer's name	Premium on redemption	Redemption date	Secured/ Unsecured	Investment Amount outstanding amount as at	
				March 31, 2026	March 31, 2025
Fortis Health Management Limited	11.50%	July 26, 2031	Unsecured	14,317.47	12,846.49
Fortis Health Management Limited	11.50%	October 19, 2027	Unsecured	32,547.74	29,209.31

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

- iv) The particulars of the investments in optionally convertible debentures for the purpose of business expansion by the Company as required to be disclosed by Section 186 (4) of Companies Act, 2013 are as follows:

(Amount in ₹ lacs)

Issuer's name	Premium on redemption	Redemption Date	Secured/ Unsecured	Investment Amount outstanding amount as at	
				March 31, 2026	March 31, 2025
Hospitalia Eastern Private Limited [Refer Note 1 below]	9% to 22% depending on Earnings before interest and tax (EBIT) of Company. At present, EBIT is less than ₹ 3,900 lacs, therefore interest rate is 9% p.a.	September 17, 2030 or prior to the maturity date by giving 6 months' notice	Unsecured	7,800.00	7,800.00

Note 1: The redemption date specified above are the dates as per the terms of the agreement. The interest on the optionally convertible debentures is receivable on monthly basis or can be deferred up to a period of 5 years on a mutual agreement basis. The Company has not received the interest amount during the current year and previous year.

- v) The particular of the investments in optionally convertible redeemable preference shares (OCRPS) by the Company for the purpose of business expansion as required to be disclosed by Section 186 (4) of Companies Act, 2013 are as follows:

Issuer's name	Premium on redemption	Redemption date	Secured/ Unsecured	Investment Amount outstanding amount as at	
				March 31, 2026	March 31, 2025
Fortis Health Management Limited (Refer Note 1 below)	NA	10 years or any time before maturity date as mutually agreed	Unsecured	100,706.71	100,706.71

Note 1: During the previous year, the Company's investment in Optionally Convertible Debentures of Fortis Health Management Limited (FHML) including interest accrued thereon stands converted into 1,007,067,149 optionally convertible redeemable preference shares of ₹ 10 each aggregating to ₹ 100,706.71 Lacs. FHML has the right to convert OCRPS into equity shares anytime during the tenure of OCRPS (conversion ratio to be fixed upfront, based on current fair market value of equity shares) or redemption at the end of the tenure.

18. Corporate social responsibility

As per section 135 of the Companies Act, 2013 and rules therein, the Company is required to spend at least 2% of average net profit of past three years towards Corporate Social Responsibility (CSR). The calculation of Corporate Social Responsibility (CSR) obligations and expenditures under Section 135 of the Companies Act, 2013 read with the rules issued thereunder for the Financial Year 2024-25, have been determined based on the audited financial statements of the Company for the relevant past period, as had been approved by the board and shareholders of the Company. Details of CSR expenses, as certified by Management, are as follows:

Particulars	March 31, 2026	March 31, 2025
(i) Amount required to be spent by the Company during the year and approved by Board	511.37	309.77
(ii) Amount of expenditure incurred	511.37	309.77
(iii) Shortfall at the end of the year,	-	-
(iv) Total of previous years shortfall,	-	-
(v) Reason for shortfall,	-	-
(vi) Nature of CSR activities undertaken by the Company	Donation to Indian cancer society towards cancer awareness, cancer detection and screening, Doctors for you, Foundation of excellence, The federation of Indian chambers of commerce and industry.	Donation to Apprenticeship Program, FICCI, Foundation of excellence, Society of Community Health Oriented Operational Links (SCHOOL) and Sattva Media and Consulting Pvt Ltd.

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Particulars	March 31, 2026	March 31, 2025
(vii) details of related party transactions, e.g., contribution to a trust controlled by the Company in relation to CSR expenditure as per relevant accounting standard,	-	-

19. Interest on delayed payment of service fees

As per the HMSA arrangement with the hospital operating company, the Company receives service fee consideration from the Hospital operating companies, as an when due. As per terms of the HMSA, in the event of any delay in payment of the Service Fee, an interest at a rate of State Bank of India base rate plus 2% per annum (on a compounded monthly basis) shall be payable by hospital operating company to the Company. The Company and hospital operating company have agreed that no interest would be charged/demanded for the delay in the payments on amounts under HMSA for the financial year 2024-25 and 2025-26 on account of the continued business relation. Consequently, the Company has not recognized interest on the delayed payment of the service fees/technology renewal fund during the year ended March 31, 2025 and March 31, 2026.

20. Ratio Analysis and its elements

S. No.	Ratios	Numerator	Denominator	March 31, 2026	March 31, 2025 (Restated)	% Change	Reason for variance
1	Current Ratio (in times)	Total current assets	Total current liabilities	0.46	0.66	(32.17%)	Due to outstanding amount received from related party
2	Debt-Equity Ratio (in times)	Debt consists of borrowings and lease liabilities	Total equity	0.83	0.79	5.17%	-
3	Debt Service Coverage Ratio (in times)	Earning for Debt Service = Net Profit after taxes + non-cash operating expenses + Finance costs + Other non-cash adjustments	Debt service = Interest and lease payments + Principal repayments	2.06	2.47	(16.56%)	-
4	Return on Equity Ratio (in %)	Profit for the year less Preference dividend (if any)	Average total equity	13.54%	13.73%	(1.34%)	-
5	Inventory turnover Ratio (in times)	Cost of goods sold	Average Inventory	19.79	20.23	(2.17%)	-
6	Trade Receivables Turnover Ratio (in times)	Revenue from operations (excluding liabilities no longer required written back)	Average trade receivable	8.16	7.51	8.60%	-
7	Trade Payables Turnover Ratio (in times)	Net credit purchases = Gross credit purchases - purchase return	Average trade payables	2.12	2.11	0.49%	-
8	Net Capital Turnover Ratio (in times)	Revenue from operations (excluding liabilities no longer required written back)	Working capital (i.e. Total current assets less Total current liabilities)	(4.68)	(6.05)	(22.58%)	-
9	Net Profit Ratio (in %)	Net Profit	Revenue from operations (excluding liabilities no longer required written back)	12.20%	12.84%	(4.94%)	-

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

S. No.	Ratios	Numerator	Denominator	March 31, 2026	March 31, 2025 (Restated)	% Change	Reason for variance
10	Return on Capital Employed (in %)	Profit before tax and finance costs	Capital employed = Tangible Net worth + Debts + Lease liabilities + Deferred tax liabilities	14.50%	16.12%	(10.08%)	-
11	Return on Investment (in %)	Income generated from invested funds	Average invested funds	3.06%	4.94%	(37.99%)	Due to increase in investment

21. Other Statutory Information

- (i) The Company does not have any charges or satisfaction which are yet to be registered with ROC beyond the statutory period.
- (ii) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- (iii) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
 - (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- (iv) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
 - (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries,
- (v) The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).
- (vi) The Company is not declared wilful defaulter by any bank or financial institution or other lender
- (vii) The Company has following transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956.

Name of the Company	Reason for continuous transactions	Nature of transaction	Balance outstanding as of March 31, 2026	Balance outstanding as of March 31, 2025	Transactions in FY 25-26	Transactions in FY 24-25
VLS Healthcare Private Limited	Business requirement	Purchase of material / services	-	-	-	0.19
Socomec Ups Private Limited	Business requirement	Purchase of material / services	2.45	-	2.45	-
Thermadyne Private Limited	Business requirement	Purchase of material / services	-	-	5.83	-
Aniket Shubham Private Limited	Business requirement	Purchase of material / services	1.47	1.47	-	-

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Indo British Garments Private Limited	Business requirement	Service Provided	(1.46)	(0.81)	0.65	(0.81)
--	-------------------------	---------------------	--------	--------	------	--------

(viii) The Company has complied with the number of layers prescribed under clause (87) of Section 2 of the Act.

(ix) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India and the Group (as defined in the regulations made by the Reserve Bank of India) does not have any CIC.

22. Exceptional Items

- a) The Company has an investment in unsecured 9% optionally convertible debentures having aggregate carrying value of ₹ 4,056.95 lacs (Net off impairment loss recognized in earlier years amounting to ₹ 3,743.05 lacs) in Hospitalia Eastern Private Limited (fellow subsidiary). During the previous year, considering the uncertainty in recoverability of the investment in the fellow subsidiaries, the Company has fully impaired its investment in optionally convertible debentures resulting in impairment loss of ₹ 4,056.95 lacs.
- b) During earlier years, Fortis Hospitals Limited had performed an impairment test for the carrying value of property, plant and equipment, intangible assets and goodwill for Faridabad hospital (CGU). The recoverable value determined based on discounted cash flows was lower than the remaining carrying value of property, plant and equipment, intangible assets and goodwill and an impairment loss of Rupees 1,879.12 lacs (including Rupees 323.05 lacs on goodwill) had been recognized for the year ended March, 31 2019. The undertaking was merged with the Company pursuant to scheme of arrangement (Refer note 24)

During the previous year, the Company has reversed impairment loss of Rupees. 286.15 lacs on property, plant and equipment (net of subsequent depreciation/ amortisation that would have been recognized if impairment had not been recognized earlier) based on improved performance and increase in recoverable value determined on the basis of discounted cash flows of the CGU.

The recoverable amount of this CGU is based on value-in-use calculations which uses discounted cash flow projections. The fair value measurement has been categorized as Level 3 fair value based on the inputs to the valuation technique used.

The key assumptions used in the estimation of the recoverable amount are set out below. The values assigned to the key assumptions represent management's assessment of future trends in the relevant industries and have been based on historical data from both external and internal sources.

(In percent)	March 31, 2025
Discount rate (post tax)	11.31
Terminal value growth rate	4.00
Compound average net sales growth rate	7.41

Management believes that any reasonable possible change in any of these assumptions would not impact reversal of impairment loss.

- c) Effective November 21, 2025, the Government of India has consolidated multiple existing labour legislations into a unified framework comprising four labour Codes collectively referred to as the 'New Labour Codes'. Under Ind AS 19, changes to employee benefit plans arising from legislative amendments constitute a plan amendment, requiring recognition of past service cost immediately in the statement of profit and loss.

The New Labour Codes have resulted in one time increase in provision for employee benefit of the Company. The estimated incremental impact of the same amounting to Rupees 1,081.63 lacs has been recognized and presented as 'One time impact of new Labour Codes' under 'Exceptional Item' for the year ended March 31, 2026. The Company continues to monitor any clarifications from the Government on other aspects of the New Labour Codes and would provide appropriate accounting effect in the relevant period based on such developments as needed.

23. During the current year, the Company has executed a sub-lease agreement with R.R. Lifesciences Pvt Ltd ("RRLPL") to sub-leasing the hospital land, building, and equipment, situated at Gautam Buddha Nagar, Greater Noida to the Company. Pursuant to this arrangement, the Company will operate the Hospital and will also employ/engage the erstwhile employees, contractors, vendors etc. of RRLPL engaged at the said Hospital. The Sub-lease Agreement is effective from September 1, 2025.

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

24 Business combination under common control

- i) The Hon'ble National Company Law Tribunal, Delhi bench, vide Order dated May 09, 2025 and the Hon'ble National Company Law Tribunal, Chandigarh bench, vide Order dated July 30, 2025, sanctioned the Composite Scheme of Arrangement amongst the Company, Fortis Hospotel Limited ('FHTL') and Fortis Hospitals Limited ('FHsL') and their respective shareholders and creditors under Sections 230 to 232 read with the other applicable provisions of the Companies Act, 2013 ('the Scheme') for demerger of the Kalyan Undertaking, Amritsar Undertaking, Faridabad Undertaking, Kolkata (Anandpur) Undertaking, FHKI Undertaking, Noida Undertaking and Mulund Undertaking of FHsL into IHL, and FMRI Gurgaon Undertaking of FHsL into FHTL with an appointed date of April 01, 2023. The certified copy of the Order was received on August 11, 2025. The certified copy of aforesaid Order was filed with Registrar of Companies, Haryana on September 01, 2025 and accordingly the Scheme has come into effect. The Scheme is applicable from the Appointed Date i.e. April 01, 2023. Accordingly, due effect of the Scheme has been incorporated from the Appointed Date. Pursuant to the Scheme, the Business of Kalyan Undertaking, Amritsar Undertaking, Faridabad Undertaking, Kolkata (Anandpur) Undertaking, FHKI Undertaking, Noida Undertaking and Mulund Undertaking (along with all assets and liabilities thereof) were transferred to the Company on a going concern basis. The transaction has been accounted for using the pooling of interest method under Appendix C to Ind AS 103 – Business Combinations, with all identified assets and liabilities recorded at their carrying values. Accordingly, the amounts relating to the year ended March 31, 2026 include the impact of the business combination for the entire year and the corresponding amounts for the previous year ended March 31, 2025 have been restated by the Company after recognising the effect of the Scheme as above.
- ii) The Company, FHsL and FHTL carries on the business of promotion, maintenance, management, operation and conduct of healthcare and related services and providing consultancy for establishment of healthcare services. Further, the Company and FHTL are also engaged in the business of providing clinical establishment services.
- iii) The following assets and liabilities were transferred to the Company as on April 01, 2023 and April 01, 2024 (i.e. the earliest period):

Particulars	(Restated)	
	Amount in ₹ lacs	
	As at April 2024	As at April 2023
ASSETS:		
NON-CURRENT ASSETS		
Property, plant and equipment	27,968.75	21,518.47
Capital work-in-progress	671.16	746.05
Right-of-use of assets	1,422.44	35.23
Goodwill	24,191.35	24,191.35
Intangible Assets	387.50	240.44
Intangible assets under development	42.00	-
Other Financial Assets	162.06	299.67
Deferred tax assets	692.31	692.31
Non-current tax assets	4,646.47	-
Other Non-Current Assets	325.39	225.92
Total Non-Current Assets (A)	60,509.43	47,949.45
CURRENT ASSETS		
Inventories	1,766.78	1,480.03
Trade Receivables	17,124.29	14,680.70
Cash and cash equivalents	179.96	179.56
Bank balances	7.12	18.64
Other Financial Assets	30,202.69	44,137.40
Other Current Assets	669.93	821.81
Total Current Assets (B)	49,950.77	61,318.14

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

TOTAL ASSETS (A+B)	110,460.20	109,267.59
Particulars	Amount	
	As at April 2024	As at April 2023
<u>EQUITY AND LIABILITIES</u>		
Other equity	53,391.74	40,500.80
Total Equity (A)	53,391.74	40,500.80
<u>NON-CURRENT LIABILITIES</u>		
Borrowings	12,091.97	8,342.16
Lease liabilities	1,354.26	34.45
Other Financial Liabilities	-	0.75
Provisions	2,765.71	2,503.86
Total Non-current liabilities (B)	16,211.94	10,881.22
<u>CURRENT LIABILITIES</u>		
Borrowings	3,678.11	4,432.01
Lease liabilities	217.48	6.91
Trade Payables	30,482.12	38,839.15
Other Financial Liabilities	3,152.87	11,282.70
Provisions	518.51	392.72
Other Current Liabilities	2,807.43	2,932.08
Total Current liabilities (C)	40,856.52	57,885.57
TOTAL LIABILITIES (B+C)	57,068.46	68,766.79
TOTAL EQUITY & LIABILITIES	110,460.20	109,267.59

iv) In accordance with the Scheme, the Company has allotted the following to the shareholder of FHsL as consideration against the transfer of business:

- 53,985,768 equity shares of ₹100 each to Fortis Healthcare Limited (FHL), and
- 10,476,793 compulsory convertible preference shares of ₹10 each to Escorts Heart Institute and Research Centre Limited (EHIRCL).

This resulted in a debit of ₹ 55,033.45 lacs to the Demerger Deficit Reserve.

INTERNATIONAL HOSPITAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

- v) Pursuant to scheme: -
- a) The borrowing availed by FHsL from the appointed date till the effective date of the scheme shall be considered to be availed on behalf of FHsL, FHTL and the Company; and liabilities discharge by FHsL from the appointed date till the effective date shall be considered to be discharged by FHsL, FHTL and the Company.
 - b) The intra-company receivables/payable in relation to the undertaking transferred from FHsL at the appointed date pursuant to the composite scheme of arrangement, shall be considered as inter-company receivables/payables by the Company with FHTL and FHsL at the appointed date.
 - c) Inter-company balances and transaction between FHsL and IHL in relation to the undertaking transferred stands cancelled at the appointed date.

For **B S R & Co. LLP**
Chartered Accountants
Firm Registration Number: 101248W/W-100022

For and on behalf of Board of Directors of
International Hospital Limited

Rakesh Dewan
Partner
Membership Number: 092212

Dr. Ananth Rao Nanjunda
Whole time Director
DIN: 11395535

Anil Vinayak
Director
DIN: 02407380

Place: Gurugram
Date: May 18, 2026

Satyendra Chauhan
Company Secretary
Membership No.: 14783

Ravi Bhatia
Chief Financial officer

Place: Gurugram
Date: May 18, 2026